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The gut mucosa is an important portal for HIV-1 transmission and infection. Therefore, a vaccine 
which can prevent virus transmission at mucosal surfaces would be an ideal HIV-1 vaccine 
candidate. Clostridium perfringens has been used as a vehicle to deliver SIV proteins in large 
quantity to the terminal ileum. A mucosal immunization strategy using C. perfringens should be 
able to induce potent mucosal immune responses against HIV-1. A recombinant C. perfringens 
expressing large amount of HIV-1 Gag protein (Cp-Gag) was constructed. Under in vitro 
conditions, Cp-Gag was found to induce bone marrow derived dendrite cell (BMDC) to mature 
and stimulate HIV-1 Gag specific T cell responses. Then in vivo experiments were performed in 
mice to demonstrate orally delivered Cp-Gag ability to prime gut mucosal T cell responses. 
Since oral tolerance is a major obstacle for orally delivered immunization approaches, a 
combination of mutated heat-labile enterotoxin of E. coli (mLT) and CpG containing 
oligodeoxynucleotides (CpG-ODN) were used as adjuvants for oral administration with Cp-Gag. 
Orally delivered Cp-Gag was tested for induction of HIV-1 Gag specific T cell responses in a 
prime-boost model with intranasal inoculation of HIV-1 virus like particles (VLP). HIV-1 
specific cellular immune responses in both the effector (Lamina propria) and inductive sites 
 iv 
(Peyer’s patches) of the gastrointestinal (GI) tract were significantly higher in mice immunized 
using Cp-Gag and VLPs in prime-boost approaches compared to mice immunized with either 
Cp-Gag or VLPs alone. Such cellular immune response was found to be mediated by both CD8+ 
and CD4+ T cells. These groups of mice also seemed to have HIV-1 specific multifunctional T 
cells in PPs and LP of the GI tract. In summary, mucosal immunization of mice with a Cp-Gag 
and VLPs in a prime-boost mode led to strong HIV-1 Gag specific cellular immune responses in 
both mucosal and systemic immune compartments. Such strong mucosal immune response could 
be very important to control HIV-1 infection at mucosal surfaces. The proposed vaccine strategy 
has great public health significance for developing a practical vaccine against HIV due to its 
safety, low production cost and easy administration. 
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1.0  INTRODUCTION 
Human immunodeficiency virus-1 (HIV-1) is a member of the genus Lentivirus from the 
Retroviridae family. Retroviruses are enveloped RNA viruses. Distinguishing features of this 
family of viruses are a life cycle which includes reverse transcription of the retroviral RNA 
genome into DNA, which is then integrated into the host genome. Simian immunodeficiency 
virus (SIV) is the nonhuman primate lentivirus most closely related to HIV-1. Therefore, SIV 
have proved a useful experimental model of HIV-1 pathogenesis. HIV-1 is the causative agent 
responsible for the current acquired immune deficiency syndrome (AIDS) pandemic, having 
spread all across the globe [2]. HIV-1 is primarily transmitted through heterosexual contact, 
although injection drug use, men who have sex with men (MSM) and mother-to-child 
transmission also constitute a considerable amount of virus transmission. Currently, there is no 
cure for AIDS, although therapies combining multiple expensive drugs have been used to lower 
viral load and ameliorate symptoms. Therefore, an effective HIV-1 vaccine to prevent infection 
is the most cost effective approach to contain the impact of HIV-1/AIDS on public health. 
1.1 THE AIDS EPIDEMIC 
Since the discovery of HIV-1 over 25 years ago, the global AIDS epidemic has become one of 
the greatest threats to human health and development. In 2007 approximately 33 million people 
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were living with HIV-1 (Figure 1). 2.7 million new HIV-1 infections and 2 million deaths due to 
AIDS occur each year [3]. 
 
 
Figure 1. The global HIV-1 epidemic in 2007. 
From the “Report on the global HIV-1/AIDS epidemic 2008” published by UNAIDS. Adapted from publicly available data from 
UNAIDS. <www.unaids.org>. Reproduced by kind permission of UNAIDS. © 2008 Report on the global AIDS epidemic. 
 
Highly active antiretroviral therapy extends the lives of infected individuals. However, 
much of the HIV-1 epidemic is due to infections in countries where access to health care and 
medicines is limited [4]. The most heavily affected region is sub-Saharan Africa, where in a few 
countries more than one in five adults is infected with HIV-1. At the end of 2007, there were 
nine countries in Africa where more than one tenth of the adult population aged 15-49 was found 
to be infected with HIV-1. In three countries, within the same continent, at least one adult in five 
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is living with the virus. Strikingly, 23.9% of adults in Botswana and 18.1% in South Africa are 
infected with HIV-1. Currently, there are approximately 22 million Africans living with HIV-
1/AIDS. The latest UNAIDS estimates indicate that 35,000 people in North Africa and the 
Middle East acquired an HIV-1 infection in 2007, bringing the total number of people living with 
HIV-1/AIDS in the Middle East and North Africa to an estimated 380,000 [3]. 
The epidemic of AIDS in Asia appears to be of more recent origin, and many Asian 
countries lack adequate systems for monitoring the spread of HIV-1. Half of the world's 
population lives in Asia, so even small differences in the infection rates can result in large 
increases in the number of people infected. In 2007, about five million people were living with 
HIV-1 in Asia including 2.4 million in India. The AIDS epidemic is rapidly increasing in Eastern 
Europe and Central Asia too, where the number of people living with HIV-1 increased 150% 
between 2001 and 2007 [3]. Therefore, it is necessary to concentrate efforts towards designing a 
safe, effective and affordable vaccine for HIV-1 to control the growing epidemic worldwide.  
1.2 HIV-1 BIOLOGY 
1.2.1 HIV-1 Virion Structure 
The HIV-1 virion is composed of two 9.2 kb RNA strands enveloped by a lipid bilayer derived 
from the membrane of the host cell (Figure 2). The genomes of HIV-1 contain three prototypic 
genes flanked by non-coding long terminal repeats (LTR) sequences. The gag gene encodes the 
structural proteins matrix, capsid, and nucleocapsid. The pol gene, encodes the viral enzymes 
reverse transcriptase (RT), protease (Pro), and integrase (In). The env gene, encodes the outer 
 3 
glycoprotein that mediates viral entry of permissive cell types. Additionally, there are six open 
reading frames (ORF) composed of two genes that are essential for replication, tat and rev [5, 6], 
and the four accessory genes HIV-1 replication, vif, vpr, vpu and nef [6].  
 
 
Figure 2. HIV-1 virion structure and genomic organization. 
A) Mature HIV-1 virion structure. Image was reproduced from a publicly available source from the Los Alamos National 
Laboratory HIV-1 Database, Los Alamos, New Mexico. www.HIV-1.lanl.gov. B) HIV-1 genomic structure. 
 
1.2.2 HIV-1 Lifecycle 
HIV-1 enters a cell by binding of viral surface protein gp120 to cellular glycoprotein CD4, 
mainly expressed on CD4+ T cells, monocytes and macrophages. This initial binding facilitates 
further binding of gp120 to two main co-receptor molecules, the chemokine receptors CCR5 (R5 
tropic virus) and CXCR4 (X4 tropic virus) on the host cell [7, 8]. This binding of co-receptors 
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promotes a conformational change of gp120 which induces fusion of gp41 on the virus 
membrane to the target host cell membrane followed by subsequent release of the viral core into 
the cell cytoplasm [9]. Following release of the viral core, the HIV-1 RNA genome is reverse 
transcribed into DNA by virion reverse transcriptase and a host of additional viral and cellular 
proteins [9]. The viral DNA is then integrated into the host cell genome. Transcription of the 
viral genome occurs in the nucleus of the host cell mediated by the viral LTR and several host 
and viral cell transcription factors. Following the synthesis of viral proteins and shuttling of full-
length copies of the viral RNA genome to the cytoplasm, the virion is assembled at the plasma 
membrane where budding occurs [7]. Generally, the structural polyproteins Gag-Pol and Env 
accumulate at the host cell plasma membrane and interact with the genomic RNA to package the 
genome into virions. Complete virions then bud from the plasma membrane. Final maturation of 
the virion occurs after budding from the cell and involves cleavage of the Gag polyprotein into a 
proline-rich protein (p6), a nucleic acid binding protein (p7), matrix (p17), and capsid (HIV-1 
p24) [10].  
1.2.3  Natural History of HIV-1 infection 
There are four major modes of HIV-1 transmission: 1) sexual intercourse, 2) blood transfusion, 
3) sharing contaminated needles from intravenous drug use and 4) mother-to-child during the 
prenatal period [11]. Many immunological and viral hallmarks are observed during the course of 
infection of HIV-1 [12, 13]. The majority of HIV-1 infected individuals follow three basic stages 
of disease progression: (i) primary or acute infection, (ii) asymptomatic (chronic) infection and 
(iii) symptomatic infection, better known as AIDS (Figure 3). 
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Primary or acute infection by HIV-1 is mainly characterized by flu-like symptoms that 
become present within 1 to 4 weeks after infection. These symptoms include sore throat, fever, 
muscle ache, swollen lymph nodes and rash [14]. Primary HIV infection is associated with a 
burst of HIV viremia and with abrupt and rapid decline of CD4+ T cell number in the peripheral 
blood. The decrease in circulating CD4+ T cells during primary infection is probably due both to 
HIV-1 mediated cell killing and to re-trafficking of cells to the lymphoid tissues and other organs 
[15]. During primary infection, HIV-1 transmission to a new host occurs and the virus targets 
CCR5+
 
CD4+
 
effector memory T cells [16, 17]. These target cells are present predominantly at 
mucosal sites of the gastrointestinal (GI) tract. As a consequence, a massive depletion of CCR5+
 
CD4+
 
cells occurs at these mucosal sites within the first few weeks of acute infection [16, 18]. 
Mucosal depletion is soon followed by a state of chronic activation resulting in 1) increased 
numbers of activated and memory T cells, 2) increased production of proinflammatory cytokines 
and 3) increased turnover of immune cells [16]. During the acute phase, viremia load can be as 
high as 106 to 107 copies/ml in plasma [14, 19]. Soon after infection, a decline in CD4+ T cells is 
observed in multiple tissues as infected cells are eliminated from the host by a number of 
mechanisms including super-antigen induced death and direct effects of the virus on the cell 
membrane and genetic material [20-22]. The CD8+ T cell response is also high during acute 
infection and its ability to control viremia during the acute phase is usually the best predictor of a 
long-term asymptomatic period [14]. Following acute stage, an infected individual enters a 
clinically asymptomatic phase (chronic disease), which can persist for an average of 10 years in 
humans [23]. The asymptomatic stage varies from individual to individual. Low levels of virus 
replication and no apparent illness or clinical symptoms are present. Moreover, there is a 
decrease in viremia which could be due to an immune response mediated by CD8+ T cell killing 
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of virus infected cells, substrate exhaustion due to the massive loss of target cells or a 
combination of both. During this time until the symptomatic phase begins (8 to 10 years in a 
typical progressor), there is a persistent low level of virus replication in the lymph nodes and 
peripheral blood, high viral genetic diversity and an increased viral replicative fitness. Low level 
virus replication is probably maintained by an antiviral CD8+ T cell response. Although this 
phase is clinically asymptomatic, the delicate balance of the host immune system and viral 
replication dynamics are at constant war; cell turnover levels are high, leading to a persistent 
state of activation resulting in chronic progressive immune dysfunction [24]. Although a robust 
immune response is mounted soon after infection with the infiltration of CD8+ T cells and 
production of proinflammatory cytokines and chemokines, it is generally too late and the 
infection is already well established. HIV specific neutralizing antibodies also arise during 
chronic infection and may help in limiting viremia [25]. 
 
 
Figure 3: Schematic of typical course of HIV-1 infection showing changes in CD4 and CD8 T cell counts in 
peripheral blood and plasma viral load.  
Figure from Munier et al., Immunol Cell Biol volume 85, 6-15, 2007 with permission from Nature publishing group. 
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The symptomatic phase is characterized by increased viral load, a decline in CD4+ T cells 
to less than 200 cells/ul bloods and a deteriorated CD8+ T cell response. During symptomatic 
phase CD4+ T cell level constantly decline and reach a level in which the individual becomes 
susceptible to AIDS-defining opportunistic infections [e.g. Pneumocystis carinii pneumonia 
(PCP)] and neoplasms [24, 26, 27]. Because HIV-1 infection immediately diminishes the 
capacity for immune response formation, a vaccine that provides immunity before HIV-1 
exposure and infection is desirable. 
There is a small percentage of individuals including: (i) high risk commercial sex 
workers (likely repeat exposure to HIV-1 virus) that do not become infected [28-30] (ii) infected 
individuals who do not exhibit evidence of disease progression over extended period of time with 
slow or no decline in CD4+T cells, termed long term non-progressors (LTNP) [31, 32], and (iii) 
‘elite controllers’ that can control virus without any treatment [33, 34]. Therefore, study of the 
HIV-1 specific immune responses in these individuals who are resistant to viral infection or 
control viral replication might shed light on the appropriate immune responses that need to be 
induced by a protective HIV-1 vaccine.  
1.3 HIV-1 AND THE MUCOSA 
The most common mode of HIV-1 transmission is through sexual contact with HIV-1-infected 
individuals. HIV-1 can enter the body during vaginal or anal sex and in some cases via oral route 
during oral sex, or through the surface tissues of the genitals [35]. The mucosa has large areas 
vulnerable to infection by pathogenic microorganisms with viral infection and replication 
observed in both urogenital and intestinal mucosa in humans and macaques [36, 37].  
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Several studies using immunohistochemistry of gastrointestinal (GI) tissues from 
chronically HIV-1-infected individuals, confirmed that the GI tract was significantly depleted of 
CD4+ T cells [38-40]. These studies have shown that intestinal lamina propria (LP) could be a 
site of rapid CD4 lymphocyte destruction during HIV infection. Similar studies performed in 
rhesus macaques have also shown that within days of infection, there is a similar dramatic 
depletion of GI tract CD4+ T cells in SIV infected animals [37, 41].  
Studying the pathogenesis of CD4+ T-cell depletion in the human GI tract during acute 
HIV-1 infection is challenging and not well defined as to why mucosal tissues are the primary 
targets for HIV-1, but it is likely that the nature of GI tract resident cells and the ability for virus 
or virally-infected cells to enter the GI mucosa contribute to infection of the GI tract. A recent 
study has shown that lymphocytes, including natural killer (NK) cells and CD4+ and CD8+ T 
cells, can bind to HIV-1 gp120 via the α4β7 gut homing molecule, suggesting a method by 
which virus is preferentially delivered to the GI tract following transmission [42]. Because 
envelope proteins remain associated with the host cell membrane following fusion, infected cells 
as well as free virus may bind to α4β7 and thus be transported to the GI tract [42, 43]. Many 
studies have examined depletion of the specific target of HIV-1: CD4+ T cells that express the 
HIV-1 co-receptor CCR5 in the gut mucosal tissues. Phenotypic analysis of CD4+ T cells in the 
GI mucosa of healthy individuals has demonstrated that the majority of T cells in mucosal tissues 
expresses CCR5 and is very permissive to in vitro infections. Such analyses have clearly 
demonstrated almost complete depletion of CCR5+ CD4+ T cells from mucosal sites of HIV-1-
infected humans and SIV-infected rhesus macaque [44-46]. Preferential targeting of CCR5+ 
CD4+ T cells is consistent with reports showing more extensive depletion from the lamina 
propria (LP) as compared with inductive sites such as Peyer’s patches (PP). The preferential loss 
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of CCR5+CD4+ T cells from the GI tract clearly suggests a “virus-centric” mechanism [38, 46]. 
Flow cytometric sorting of precisely defined T-cell subsets followed by quantitative polymerase 
chain reaction for viral DNA have shown that CD4+ T cells in the GI tract are 10-fold more 
frequently infected by the virus than are those in the peripheral blood [47, 48]. It has also been 
shown that about 60% of GI CD4+ T cells are infected by the virus in vivo [49].  
The mechanisms underlying this phenomenon are not well defined but they have been 
explored extensively. In one PCR based study using the SIV model, it was demonstrated that at 
peak viremia (10 days post infection) 30 to 60% of memory T cells throughout the body 
(including the GI tract) are infected by SIV and suggested that direct viral cytopathicity is 
responsible for CD4+ T-cell depletion in the intestines [47, 48]. Contemporaneously, another 
study suggested that the effects of direct viral infection alone could not account for the magnitude 
of GI CD4+ T-cell loss, since only 7% of GI CD4+ T cells were found to contain HIV-1 RNA 
[50]. These researchers based their findings on in situ hybridization as opposed to PCR-based 
techniques, which may account for the observed differences. Nevertheless, they found that SIV 
infection triggers Fas-Fas ligand-mediated apoptosis in lamina propria CD4+ T cells and 
concluded that direct viral cytopathicity and indirect effects such as apoptosis of infected and 
uninfected CD4+ T cells are both involved in the pathogenesis of mucosal CD4+ T-cell depletion 
[48]. Therefore a mucosal HIV-1 vaccine is needed that can elicit a robust immune response in 
the GI tract to prevent the massive depletion of CD4+ T cells in this mucosal tissue. 
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1.4 THE IMMUNE RESPONSE TO HIV-1 INFECTION 
Both humoral and cellular components of the immune system generate a response against HIV-1 
infection. Although initially these responses are able to control the viral load during the acute 
phase of the infection, there is no complete clearance of the virus. HIV-1 is able to persist by 
integrating into the chromosomes of resting T cells and thereby creating a latent reservoir, which 
marks the chronic phase of infection. In addition, due to the ability of HIV-1 to easily develop 
mutations that confer resistance against the initial immune response, HIV-1 is slowly able to 
escape immune control and ultimately progress to AIDS. 
1.4.1 CD8+ T cells in HIV-1 infection 
It is known that CD8+ T cells recognize peptides presented within the binding cleft of MHC class 
I (MHC-I) molecules. Most cells present peptides derived only from endogenous proteins on 
MHC-I molecules and, by doing so, become targets of the effector function of CD8+ T cells. 
HIV-1-specific cytotoxic T lymphocytes (CTLs) recognize cells displaying viral antigen on 
MHC-I, which generally denotes viral infection of that cell. Upon recognition, CTLs induce 
apoptosis of the infected cell by one of two mechanisms. First, signal transduction initiated by 
the binding of FasL on CD8+ CTLs to Fas on target cells engages the caspase cascade, leading to 
apoptosis [51, 52]. Second, and most commonly, CTLs degranulate, releasing perforin and 
granzyme proteins from intracellular lytic granules into the space between the CTL and its target 
[53]. Monomeric perforin inserts into the target cell plasma membrane and can polymerize to 
form pores through which granzyme can use to enter the target cell. Granzymes are serine 
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proteases which can cleave cellular proteins to initiate the caspase cascade and therefore lead to 
death of the target cells via apoptotic pathways. 
The responses of HIV-1 specific CD8+ T cells or cytotoxic T lymphocytes (CTL) appear 
to play an important role in the control of viral replication during natural history of HIV-1 
infection. Early studies showed that the HIV-1 specific CD8+ T cell responses emerge during 
acute infection coincident with initial control of primary viremia [54-56]. Potent cellular immune 
responses have also been reported in long-term non-progressors [57], and in individuals with 
specific HLA alleles and the breadth of HIV-1 Gag-specific T lymphocyte responses have been 
correlated with control of viral replication in HIV-1-infected individuals [58, 59]. These data 
indicate the potential importance of cellular immune responses in immune control of HIV-1. 
Depletion of CD8+ T cells in SIV-infected macaques, a non-human primate model of HIV-1 
infection, results in increased viral load and more rapid disease progression [60]. Strong vaccine-
induced CTL responses in monkeys can control viral load and maintain CD4+ T cells following 
challenge with SIV [61]. Therefore CD8+ T cells play a key role in both systemic and mucosal 
immune responses to HIV-1. 
Mucosal CD8+ T cell responses are key to the control of viremia at the mucosal site of 
infection and limiting the extent of the viral spread in the body [62]. During the first few days of 
infection, there are only a few virus-infected cells in the mucosal tissues of vagina or rectum [63-
65]. The presence of CTLs at these sites during this period should be able to prevent the spread 
of infection to other tissue compartments. On the other hand, the lack of CTL responses in these 
sites will lead to increased viral replication and subsequent spread of virus to other tissue 
compartments including secondary lymphoid organs like lymph nodes and the GI tract. The 
presence of antigen specific CD8+ T cells in the colon has been associated with lower viremia in 
 12 
monkeys [66, 67]. Also vaccine induced SIV specific CD8+ T cells in the GI tract of monkeys 
abrogated or led to a milder productive SIV infection on mucosal challenge of these vaccinated 
monkeys [68, 69]. Therefore an HIV-1 vaccine must induce strong CTL responses at mucosal 
sites to be effective in protecting against mucosal HIV-1 infections.  
1.4.2 CD4+ T cells in HIV-1 infection 
The CD4+ T cells play a key role in the generation of immunity by providing appropriate ‘help’ 
for the development of humoral and cell mediated immune responses. The CD4+ T cells are 
important for their help in the maintenance of CD8+ T cell functions during chronic infections 
[70, 71]. For humans, loss of CD4+ T cells during HIV-1 infection often precedes or is associated 
with CD8+ T cell dysfunction and AIDS progression [72]. CD4+ T cells also appear to play an 
important role in the optimal priming of CD8+ T cells during acute infections [73, 74]. The 
common finding of these recent reports is that secondary expansion of memory CD8+ T cells 
following re-stimulation is dramatically reduced if the CD8+ T cells were originally primed in 
the absence of CD4+ T cells [75].  
The massive depletion of CD4+ T cells during acute HIV-1 infection occurs 
predominantly in the CCR5+ memory population, which is the major population found in the GI 
tract [18]. Similar depletion of CD4+ memory T cells has also been found in SIV-infected 
monkeys [47, 50, 76]. The depletion of these CD4+ memory T cells is a result of induction of cell 
death by both direct infection and bystander cell killing of these cells [77]. It has been reported 
that at the peak of viremia, more than 80% of CD4+ memory T cells can die, of which only a 
fraction of cells are infected [47]. It has also been suggested that the level of depletion of GI tract 
CD4+ memory T cells correlates with the time to the development of AIDS [78].  
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1.4.3 Multifunctional T cells and HIV-1 infection 
Virus-specific CD8+ T cells contribute to viral control by directly killing of virus-infected cells, 
secreting antiviral factors, and chemotactic factors that recruit other cells of the immune system 
[79]. Although virus-specific CD8+ T cells are often measured by a limited number of 
parameters, such as IFN-γ and/or IL-2 secretion, the functional profiles of T cells are certainly 
more diverse. For example the correlation between IFN-γ production and health of HIV-1-
infected individuals is weak and IFN-γ levels in vaccinated individuals do not correlate with 
protection [80-82]. The production of IFN-γ is only one of several features of activated, effective 
antigen-specific anti-viral T cells. IL-2 and tumor necrosis factor alpha (TNF-α) production are 
also key determinants of T cell survival and anti-viral effectiveness, respectively.  
IL-2 is a growth factor that is secreted by T cells to promote the proliferation and 
differentiation of antigen specific T cells in an attempt to respond to pathogenic infections 
swiftly and efficiently. Typically IL-2 is considered one of the CD4+ T cell cytokines but CD8+ T 
cells are also quite capable of producing IL-2. Unlike CD4+ T cells though, CD8+ T-cell 
production of IL-2 is typically much more restricted. The selective impairment of IL-2 secretion 
following TCR stimulation is a critical determinant of immune dysfunction during HIV-1 
infection, resulting in the inability of HIV-1-specific CD4+ T cells to mediate protective 
immunity upon restimulation [83-85]. IL-2 secretion thus serves as a reliable marker of 
functional HIV-1-specific CD4+ T cells. 
TNF-α is mainly produced by monocytes and macrophages but can also be secreted by T 
cells, natural killer cells, basophils, eosinophils, dendritic cells, neutrophils, and mast cells [86]. 
TNF-α synthesis can be stimulated by viral infections and help in the controlling viral 
replication. In the case of T cells, engagement of the TCR triggers TNF-α release, which 
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amplifies the Th1 response by inducing the synthesis of IL-12 and IL-18 [87]. These factors are 
important in up regulating IFN-γ production. TNF-α can alternatively kill virally infected target 
cells by binding its cognate receptor on their cell surface. This phenomenon is due to the fact that 
the TNF receptor contains an intracellular ‘death domain’ which triggers an apoptosis signaling 
cascade [87, 88]. 
The cytotoxic capacity of CD8+ T cells is imperative in HIV-1 virus control. Cytotoxicity 
can be assayed by the detection of CD107a and b on the surface of T cells after they have 
released the granzyme and perforin molecules from their lytic granules [81, 89]. CD107a can be 
detected on the surface of CD8+ T cells although these molecules are not normally found on the 
surface of CD8+ T cells but are found in the cytotoxic granule membrane [90]. Therefore only 
after the degranulation of activated CD8+ T cells, CD107a and b molecules are made accessible 
on the cell surface for direct labeling by specific antibodies. Therefore CD107a has been 
associated with the cytotoxic capacity of CD8+ T cells. The chemokines macrophage 
inflammatory protein [MIP-1α or MIP-1β] can also be found in cytotoxic granules, the latter type 
of which is upregulated rapidly upon activation [91].  
Flow cytometry has revolutionized the HIV-1 field by allowing researchers, to measure 
multiple parameters and T cell effector functions at the single cell level [92]. This has been 
especially powerful in the measuring of phenotype T cells including CD8+ and CD4+ T cells and 
their classification as naïve, effector, central memory, or effector memory [93-95]. These can be 
further combined with the functional correlates (IFNγ, TNFα, IL-2, CD107a and b, perforin, 
granzyme A and B) which have been termed as ‘functional signatures’ [96, 97]. Understanding 
these functional patterns of antigen-specific responses is likely to lead researchers to the crucial 
missing pieces of viral control in acute and chronic infections. Multiparametric flow cytometry 
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has been used to examined five or more functions of CD8+ T cells (surface CD107a mobilization 
for degranulation and IFN-γ, IL-2, MIP 1β, and TNF-α production) in HIV-1-infected 
progressors and non-progressors and found that non-progressors preferentially maintain HIV-1-
specific CD8+ T cells that have all five functions on a cell-by-cell basis [98].  
The association between maintenance of this multifunctional phenotype of effector CD8+ 
T cells and non-progression suggests that multifunctional CD8+ T cells are an important 
component of a protective immune response. Growing evidence supports the concept that 
evaluation of the multifunctionality of T cells displaying more than three of the functions of the 
cytokine production, IFN-γ, TNF-α , IL-2, and degranulation via CD107a/b surface expression 
are more often detectable in individuals with low viral loads and healthy levels of CD4+ T cells 
[98-105]. However, whether a vaccine can induce sustained levels of multifunctional T cells and 
whether such responses are associated with protection against viral challenge are unknown. But 
definitely understanding these functional patterns of antigen-specific responses is likely to lead 
researchers to the crucial missing pieces of viral control in acute and chronic infection. 
1.4.4 Antibody responses in HIV-1 infection 
Virus neutralizing antibody titers represent key immune correlates of protection for most 
licensed viral vaccines, and thus early studies focused on developing immunogens derived from 
HIV-1 envelope subunits. However these immunogens failed to generate protective immunity 
and were largely unsuccessful in clinical trials [106, 107]. Despite these early setbacks, 
neutralizing antibodies (NAbs) remain a major focus for HIV-1 vaccine development. A number 
of rare human NAbs have been isolated from HIV-1–infected patients that indeed do broadly 
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neutralize diverse HIV-1 strains, such as NAbs 2F5 and 4E10 against the gp41 membrane 
proximal region and NAb 1b12 reactive with the gp120 CD4-binding site [108-111].  
HIV-1 envelope constructs made in the laboratory express the binding sites of these 
antibodies (i.e., they are antigenic), but when these HIV-1 envelopes are injected into animals or 
human subjects, they do not induce broadly neutralizing antibodies [108, 110, 111]. It is poorly 
understood why HIV-1 infected individuals fail to induce broadly neutralizing antibodies with 
specificities like the rare human NAbs. The causes of poor envelope immunogenicity might be 
due to a combination of various factors. The HIV-1 envelope is heavily glycosylated, with up to 
40% of envelope mass carbohydrate creating an envelope glycan shield [110]. Also the HIV-1 
envelope is quite flexible and confers a considerable energy barrier to B cells that would 
recognize broadly neutralizing epitopes. Therefore the construction of vaccine vectors that elicit 
broad neutralizing antibodies against HIV-1 remains a challenge and is a potential roadblock in 
the development of a successful HIV-1 vaccine. 
1.5 HIV-1 VACCINES 
Developing a safe and effective preventive HIV-1 vaccine is a critical priority in the overall plan 
to contain the global AIDS epidemic. However, progress on the development of a vaccine has 
been slow since the AIDS epidemic was first recognized in 1981. An effective HIV-1 vaccine 
should be able to stimulate both types of immune responses: a humoral response, in which B 
cells produce neutralizing antibodies against the viral surface glycoprotein to target free virus 
[112] and a cellular response, in which T cells lead to the elimination of already infected cells. 
These two types of immune responses have been implicated in control of HIV-1 infection. The 
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direction in which the immune response is swayed depends upon the cytokine environment in 
which it is formed. A Th1-type environment, dominated by interferon gamma (IFN-γ) and 
interleukin (IL)-12, promotes the generation of mature CD8+ T cell responses and these CD8+ T 
cells develop into cytotoxic T lymphocytes (CTLs) which play an important in the elimination of 
virus infected cells and therefore are important in virus clearance [113]. CTLs at sites of mucosal 
transmission are important for preventing viral spread [114, 115]. A Th2-type environment, 
dominated by IL-4, promotes B cell response maturation and antibody production. Much of the 
cytokine production driving Th1- or Th-2 responses occurs in activated CD4+ T cells, although 
other cells also play vital roles. Therefore, CD4+ T cells are essential for an immune response 
since they provide co stimulatory signals and produce cytokines that lead to activation of viral 
specific B and T cells [116].  
1.5.1 Current HIV-1 vaccine candidates 
The development of a safe, globally effective, easy to administer and affordable HIV-1 vaccine 
is the best hope for controlling the AIDS pandemic. There has been much intense research going 
on in this field and significant progress has been made. [117]. Multiple vaccine concepts and 
vaccination strategies have been tested, including DNA vaccines, subunit vaccines, live vectored 
recombinant vaccines and various prime-boost vaccine combinations. More than 35 vaccine 
candidates have been tested in Phase I/II clinical trials, involving more than 10,000 volunteers 
[117, 118], and two Phase III trials have been completed, themselves involving more than 7500 
volunteers [119].  
In a recent setback to the HIV-1 vaccine field, an adenovirus type 5 (Ad5) based vaccine 
developed by Merck and NIH failed to provide protection against HIV-1 infection in the 
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randomized STEP study [120]. The vaccine was made up of a recombinant replication-
incompetent adenovirus type 5 (Ad5) that expresses the relatively well-conserved HIV-1 gag, 
pol, and nef genes from subtype B strains of HIV-1 and was aimed to prevent infection or reduce 
early viral burden though the induction of T-cell immunity alone. The results show the vaccine 
failed to achieve either objective, and suggest an increase of HIV-1 infection rate in male 
participants on the vaccine (4.6%) compared with controls (3.1%, p=0.07) [121]. Although the 
reasons for failure in this vaccine trial are unknown, it is suspected that lack of humoral antibody 
and mucosal immune response, and preexisting immune response to Ad5 may have contributed 
to such lack of efficacy of vaccine to prevent HIV-1 transmission. Therefore, future candidate 
HIV-1 vaccines probably must induce immunity in both mucosal and peripheral blood 
compartments, and also yield protective humoral responses in addition to inducing cellular 
responses. It has also been speculated that the use of more than one vector in heterologous prime 
boost approaches might be better in inducing protective immune responses than repeated 
administration of the same vector, as was the case in the STEP trail. 
The heterologous prime-boost vaccination approach has been shown to be an efficient 
way to induce T cell responses in animals and in humans. Sequential immunization with two 
different replicating recombinant viral vectors was found to induce a strong CD8+ T cell 
response against malaria [122]. Further studies in mice have shown that the heterologous prime-
boost strategy with two different vectors encoding the same antigen is more efficient in inducing 
cellular immune responses than the use of a single vector [123, 124]. Studies in nonhuman 
primates have revealed that the prime-boost approach induces strong cellular immune responses 
and can lead to protection against diseases such as malaria or SIV in primates [61, 125]. 
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We have still not been successful in making an effective HIV-1 vaccine, due to multiple 
hurdles and challenges. The development of a safe and effective vaccine is hampered by the high 
genetic variability of the virus [117, 126], the lack of knowledge of immune correlates of 
protection [127, 128], the difficulty of generating broadly neutralizing antibodies [112], the 
absence of relevant and predictive animal models and the complexities related to the preparation 
and difficulty in conducting multiple large-scale clinical trials, especially in developing countries 
[117, 129, 130]. There are several ongoing efforts in developing novel HIV-1 vaccines, which 
use new approaches. More intense and elaborated research on mucosal immunology has shown 
the path for these newer vaccine approaches. 
1.5.2 Mucosal HIV-1 Vaccines 
In general mucosal vaccines using oral or nasal routes have the potential advantages of being 
painless, easy to administer on a large scale and easy to store, and deliver than current systemic 
vaccine technologies [131-133]. Since most of the HIV-1 infections are transmitted through 
rectal and vaginal mucosal contact, it is imperative for a successful vaccine to induce immunity 
at the mucosal surface. Vaccination at a mucosal tissue stimulates local immunity in that tissue 
and usually also induces systemic immune responses detectable in the blood, spleen, and 
peripheral lymph nodes. This is in contrast to systemically delivered vaccines, which are 
generally incapable of or limited in the ability to stimulate an immune response in mucosal 
tissues. [131]. 
 The development of a mucosal HIV-1 vaccine has been pursued for many years. 
Vaccines targeted to the nasal, oral, rectal, and urogenital mucosa and to mucosal draining lymph 
nodes are under investigation [134, 135]. Antigen delivery has been tested using attenuated live 
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virus, killed virus, recombinant virus, DNA, dendritic cells and peptides. Oral immunization 
strategies have been shown to induce good immune responses in the GI tract [136, 137], whereas 
nasal immunization strategies have been reported to induce robust immune responses in the 
respiratory and genitourinary tract [138]. Therefore a mucosal immunization strategy using both 
oral and nasal routes should be able to induce potent immune responses at most of the mucosal 
surfaces. The mucosal immune responses can also be optimized by the choice of delivery system 
for the vaccine components. Several bacterial and viral vaccine vectors are currently being 
considered as HIV-1 vaccine candidates and some of these are known to generate strong mucosal 
immune responses, depending on how they are administered.  
Scientists are also looking at how substances called adjuvants delivered along with the 
vaccine candidate can be used to improve the mucosal immune responses induced. Adjuvants are 
already used with several licensed vaccines for other diseases to boost the level of immune 
responses and their duration. Several research groups are looking at novel substances that can 
specifically increase the production of antibodies and immune cells at mucosal surfaces.  
Live-attenuated virus has been shown to be very effective at eliciting protective immune 
responses against HIV-1 in non-human primate models [139, 140]. However, live-attenuated 
virus vaccines for HIV-1 has limit in human due to safety issues. The most significant safety 
issue is the potential of live-attenuated HIV-1 to revert to a pathogenic form after inoculation, as 
well as the possibility to recombine with wild-type virus in an infected host.  
 An alternative approach to live-attenuated virus vaccines for HIV-1 is the use of virus-
like particle (VLP) vaccines. VLPs, or pseudovirions, are self-assembling, non-replicating, non-
pathogenic, genomeless particles that are similar in size and conformation to intact virions. 
These immunogens can be administered as purified particles or as DNA plasmids expressing the 
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viral proteins to form VLPs in vivo [139]. Several successful VLP vaccines have been developed 
and tested in human trials attesting to the efficacy of HIV-1 VLPs as a promising HIV-1 vaccine 
candidate [141, 142]. Studies on HBV and HPV VLP vaccines have revealed a number of 
characteristics in the context of the induction of immunity. HBV VLP vaccines are effective in 
priming cellular and humoral responses and have been successfully used for hepatitis B 
vaccination [143, 144]. Intranasal delivery of VLPs seems more efficient and requires lower 
doses of antigen than oral delivery [141]. VLPs are easy to make and highly immunogenic. 
Therefore VLPs can be used as a potent mucosal HIV-1 vaccine candidate. 
Systemically delivered viral vectors can induce mucosal immune response formation 
against HIV-1 or SIV, most notably in the gut, rectal, and genital mucosa [145, 146]. However, 
the strength of these responses is generally poor. For example, Ad-vectored vaccines have been 
shown to induce low levels of mucosal immune responses after systemic inoculation, which are 
approximately 10 times less than the immune responses induced at systemic sites [145, 146]. 
Mucosal immune responses have also been seen in individuals inoculated intramuscularly with a 
pox-based vector [147]. But overall it is widely accepted that direct delivery of antigens to 
mucosal site achieves more effective mucosal immunity [114, 131, 148]. However there are very 
few mucosal vaccines against any infectious disease and the mucosal vaccines already available 
provide protection via induction of antibody responses. There are no current mucosal vaccines 
that are known to induce strong protective cellular immune responses. Therefore understanding 
biology of the mucosal immune system to develop better mucosal vaccines that can induce both 
humoral and cellular immunity is important. 
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1.6 THE BIOLOGY OF MUCOSA  
The major obstacle in mucosal vaccine development is the challenge of induction of immunity in 
the mucosa. While the systemic immune system readily responds to most foreign molecules with 
responses that eliminate the foreign particle, the mucosal immune system is more selective in the 
molecules to which it produces responses that destroy foreign particles The necessity of the 
mucosa to co-exist with environmentally acquired non-pathogenic molecules (i.e. food) and 
organisms (i.e. beneficial commensal bacteria) indicates that an intricate system exists to discern 
between safe and toxic antigens acquired at mucosal surfaces. 
1.6.1 Anatomy of the mucosal immune tissue 
The gut-associated lymphoid tissue (GALT) is the largest component of the lymphoid organ 
system and is divided into inductive and effector sites. Inductive sites are comprised of organized 
lymphoid tissues such as the Peyer’s patches and the draining mesenteric lymph nodes, which 
are distributed throughout the wall of the small and large intestines. In contrast, the effector sites 
consist of lymphocytes scattered in a less organized fashion throughout the epithelium and 
lamina propria of the gut mucosa [131, 132] (Figure 4). 
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 Figure 4. The gastrointestinal immune system. 
Adapted from “The biology of oral tolerance and issues related to oral vaccine design”. Poonam P. Curr Pharm Des. 2007 vol 13, 
2001-7 
1.6.1.1  Peyer’s Patches 
The Peyer’s patches (PPs) are highly specialized lymphoid follicles in the small intestinal wall 
that contain naïve B cells, follicular dendritic cells (FDCs), and T cells [149]. PPs are separated 
from the lumen by a monostratified epithelium called follicle-associated epithelium (FAE), and a 
subepithelial dome (SED) containing numerous DCs. The FAE is characterized by the presence 
of microfold (M) cell. M cells are specialized in the capture and translocation of microorganisms 
and particulate antigens from the lumen to the underlying SED. In the SED, antigens can be 
captured and processed by antigen-presenting cells (APCs), such as DCs [150]. Following 
antigen uptake, these DCs present the antigen to specific CD4+ T cells, either in the thymus 
dependent areas (TDA) of the PPs or in the T cell rich areas of the draining lymph node 
following migration to it. Primed T cells are induced to express the α4β7 integrin and the CCR9 
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chemokine receptor molecules that lead to the recirculation of these differentiated T cells into the 
bloodstream and ultimately the migration of these cells into the intestinal tissues [132]. This 
mechanism is a possible explanation of the anatomic compartmentalization of the mucosal 
immune response and the mechanism by which antigen delivery to mucosal surfaces can trigger 
immunity at local and distal sites.  
1.6.1.2  Mesenteric Lymph Nodes 
s) are highly organized lymphoid structures and the largest 
1.6.1.3  Lamina Propria 
f the GI tract is a meshwork of connective tissues underlying the GI 
The mesenteric lymph nodes (MLN
lymph nodes in the body. MLNs are a part of the intestinal immune system and these are defined 
as draining lymph nodes that are connected to PPs, lamina propria, and to the peripheral immune 
system through afferent or efferent lymphatic vessels. The lymphocytes that are primed in the 
PPs exit through the afferent lymphatic vessels to the MLNs. Then, they migrate into the 
bloodstream through the thoracic duct and accumulate in the mucosa [132]. Accumulation of 
lymphocytes in the MLNs requires both L-selectin and α4β7 integrin adhesion molecules, which 
normally direct lymphocytes to enter peripheral and mucosal tissues, respectively [150]. As a 
result of these unique anatomical features, the MLNs might be at crossroads between the 
peripheral and mucosal recirculation pathways. 
The lamina propria (LP) o
epithelium that contains a broad spectrum of myeloid and lymphoid cells. The intestinal LP 
appears to contain DCs that are exposed to intestinal luminal antigens. These DCs present 
antigen locally or they immigrate to distant sites where they may prime T cells against intestinal 
derived antigens [151]. LP is also important for intestinal immune responses since orally 
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delivered antigens are presented by resident DCs in the LP, and the MLNs appear to contain 
mostly DCs that have migrated from the LP and not from PPs [152-154]. LP associated DCs 
have been shown to either uptake intestinal antigens that appear in the LP or directly sample 
luminal antigens by extending dendrites through the epithelium [155, 156]. 
1.6.2 The Mucosal Immune System 
The mucosal immune system is an important first line of defense against infection. The mucosal 
e various sites of the mucosal immune system are interconnected and show a lot of 
similar
surface is a major natural route of HIV-1 entry and the GALT is a major site of early HIV-1 
replication [37, 41, 157]. The GALT comprises inductive immune tissue that collect antigen 
from the mucosal surface and generate immune responses against pathogens present in the GI 
tract. PPs, isolated lymphoid follicles, and the appendix make up the GALT, and it is in these 
tissues that most gut mucosal B and T cell immune responses are primed. PPs are the major 
GALT structure in the small intestine, where they are concentrated in the terminal ileum in 
humans. 
Th
ities in overall mucosa structure. Therefore, generation of a protective immune response 
in one mucosal area is able to afford protection at other mucosal sites [158, 159]. Therefore, 
mucosal antigen delivery can induce mucosal immunity at local and distal sites as well as 
systemic immune responses [147, 158, 159]. For example oral immunization against typhoid 
using Salmonella typhi vector has been shown to induce immune responses in the small intestine, 
ascending colon, mammary and salivary glands, although it is relatively inefficient at evoking 
response in the distal segments of the large intestines, tonsils or the female genital tract mucosa 
[159, 160]. On the other hand, intranasal immunization in humans results in strong immune 
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responses in the upper airway mucosa and regional secretions (saliva, nasal secretions) but weak 
immune responses in the gut [113, 159].  
1.6.3 HIV-1 and the mucosa 
The most common way that HIV-1 can be transmitted is through sexual contact with HIV-1-
1.6.4 Challenges in development of mucosal vaccines  
Mucosal vaccines against any infectious disease have historically been difficult to generate. Of 
infected individuals. HIV-1 can enter the body during vaginal or anal sex and in some cases 
through oral sex, through the surface tissues (mucosa) of the genitals [35]. The mucosal surfaces 
have enormous surface areas that are vulnerable to infection by pathogenic microorganism. 
Infection and replication of virus have been observed in both urogenital and intestinal mucosa in 
humans and macaques [36, 37]. Several studies have shown that there is a similar dramatic 
depletion of GI tract CD4+ T cells in HIV-1 infections [38-40]. Therefore, because of the 
significance of GI tract T cells in HIV-1 infection, the development of a strong cellular immune 
response in the intestine should be a major function of a mucosal vaccine against HIV-1.  
the over 55 licensed vaccines in the United States, only 7 are delivered mucosally, 6 through the 
oral route and one intranasally. By and large, the effectiveness of these mucosal vaccines are 
wholly dependent upon the production of humoral, not cellular responses [159]. This underscores 
the difficulty that the scientific community has experienced in developing mucosally delivered 
vaccines that induce antigen-specific CD8+ T cell responses. Ongoing studies of novel mucosal 
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vaccine vectors may provide ways to induce cellular responses in addition to humoral responses 
at both mucosal and systemic sites. 
1.6.4.1 Mucosal tolerance and the use of adjuvants 
Oral vaccines represent an attractive approach for immunization against various mucosal 
infections due to their importance in eliciting protective immune responses both at mucosal and 
systemic sites; and also due to their ease of administration. However, despite many attractive 
features, developing an oral vaccine has often been difficult. A major obstacle in the 
development of orally delivered vaccines has been oral tolerance and therefore only a few oral 
vaccines have been approved for human use; such as vaccines against polio virus [161], 
Salmonela typhi [162], V. cholera [162] and rotavirus [163]. These vaccines are derived from 
live attenuated pathogens and have a major drawback of potential reversion of the attenuated 
strain to the wild type pathogenic strain. Therefore there is a need for the development of oral 
vaccines other than the live attenuated oral vaccines, which can be used as a mucosal vaccine 
against various mucosal infections. 
Adjuvants have been used in oral immunization to overcome tolerance and direct the 
immune response either towards a Th1 or Th2 type response. The best known mucosal adjuvants 
are the secreted enterotoxin of V. cholerae and E. coli - cholera toxin (CT) and the E. coli heat 
labile enterotoxin (LT) respectively [164, 165]. These two enterotoxins are commonly used as 
adjuvants in small animal models. Both enterotoxins have almost similar immunological and 
physiochemical functions. Mutated form of LT (mLT) has been used as an adjuvant and was 
shown to induce both Th1 and Th2 immune responses, and when used in SIV vaccine 
formulations, it led to enhanced SIV-specific CTL levels [164, 166]. Furthermore, the safety of 
mLT adjuvant has been demonstrated in mice, nonhuman primates and humans [167].  
 28 
The toll-like receptor-9 (TLR-9) ligand - synthetic oligodeoxynucleotides containing 
unmethylated CpG dinucleotide motifs (CpG ODNs) is another promising mucosal adjuvant.  
CpG ODNs directly stimulate B cells and DCs, thereby promoting the production of Th1 and 
pro-inflammatory cytokines and the maturation/activation of professional antigen-presenting 
cells. CpG ODNs are effective as a mucosal adjuvant with intranasal delivered antigen [168, 
169] and has shown to enhance adaptive Th1 humoral and cellular immune responses in mice 
and primates [170]. 
Apart from the natural adjuvants, synthetic components have also been used widely as 
adjuvants. Liposomes, which are phospholipid vesicles, have been evaluated both as adjuvants 
and as a delivery system for antigens and adjuvants and have been successfully used in numerous 
mucosal vaccination studies [171, 172]. Immune stimulating complexes (ISCOMS) have also 
been used to as adjuvants to enhance immune responses and present another attractive way to 
design oral vaccine vectors. ISCOMS are about 40 nm small particles and are made of Quil A (a 
potent adjuvant), cholesterol and phospholipids which can entrap multiple antigens [173]. 
ISCOMs have been used for parenteral immunization as well as for mucosal delivery of antigens 
[174]. Antigens from viral, bacterial and parasitic sources have been used with ISCOMS and 
they were able to boost both humoral and cellular responses against these antigens [173]. 
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1.7 CLOSTRIDIUM PERFRINGENS VECTOR AS A MUCOSAL VACCINE 
CANDIDATE 
Antigen delivery has been tested using attenuated live virus, killed virus, recombinant virus, 
DNA, dendritic cells and peptides. Recently the potential for recombinant bacteria to be used as 
vectors has been investigated. HIV-1 or SIV vaccine vectors have been designed using 
Salmonella typhimurium, Shigella flexneri, and Listeria monocytogenes [175-177]. A non-
cytotoxic (cytopathic gene deleted) Clostridium perfringens, a gram positive, anaerobic 
bacterium, has been used in our laboratory to deliver a large amount of SIV proteins to the 
mucosal surface of the small intestine, especially to the GALT [1]. C. perfringens type A is a 
normal flora bacterium of the intestines of humans and other animals [178]. A small percentage 
(<1 %) of C. perfringens isolates produce an enterotoxin (CPE) that causes a mild food 
poisoning and some mild nonfood borne GI diseases. When foods contaminated with cpe-
positive vegetative C. perfringens are ingested, conditions in the upper GI tract induce C. 
perfringens sporulation, which results in the expression of CPE protein that causes diarrhea 
[179]. Since mucosal surfaces are naturally exposed to C. perfringens in the lumen, therefore C. 
perfringens derived vectors can be potent vehicles to deliver immunogens to the lymphoid 
tissues of the gut and may stimulate strong mucosal immune responses without much safety 
concerns [1].  
The unique characteristics of the biology of C. perfringens make it an attractive model 
for the development of a mucosal vaccine against HIV-1. These unique features include the 
presence of the cpe gene, which has a very strong promoter that leads to the expression high 
levels of cpe protein (15% of total bacterial protein) and induction of this promoter occurs only 
during the sporulating phase in the C. perfringens life cycle [180]. Therefore the cpe promoter 
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can be used to drive HIV-1 antigen production by making a recombinant C. perfringens 
construct in which the cpe gene will be replaced with that of the desired viral gene leaving the 
cpe promoter region intact. Removing the cpe gene from the bacteria will also make it 
nonpathogenic with respect to GI diseases. Furthermore, since the cpe protein is present in the 
form of inclusion bodies in the cytoplasm of the sporulating cell, it will be able to survive the 
harsh digestive environment of the intestine. Therefore the desired viral protein should also be 
protected and thus will be available for inducing immune responses [181].  
These unique features make C. perfringens a better oral vaccine delivery model than 
other oral vaccine models involving attenuated gastrointestinal microbes, such as Listeria 
monocytogenes [175], Salmonella typhimurium [176] and Shigella flexneri [177], none of which 
has a strong promoter. Furthermore, although these microbes are attenuated, safety of using these 
microbes as vaccines is of great concern, because of their potential reversion into wild types in 
vivo. C. perfringens, on the other hand, because of the deletion of the cpe gene, is least likely to 
revert to wild type in vivo.  
1.7.1 Safety concerns of recombinant C. perfringens expressing HIV-1 proteins 
Despite the fact that most C. perfringens bacteria rapidly undergo sporulation in the intestine, 
rendering it non replicative and dormant, one of the safety concerns of utilizing C. perfringens as 
an oral vaccine vector is that C. perfringens carries a variety of toxin-encoding genes which can 
lead to disease. Although the C. perfringens type A that has been used in developing earlier 
vaccine vectors was devoid of the Cpe enterotoxin, it still carries two other exotoxins, α-toxin 
(also known as phospholipase C) and θ-toxin (also known as perfringolysin O). Oral inoculation 
of C. perfringens carrying these two genes is considered safe in normal humans, and it is only 
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when such bacteria enter deep wounds that they are associated with disease, namely gas 
gangrene. However, there is the potential for C. perfringens delivered to the GI tract to cross the 
mucosal tissue lining and enter the underlying tissue, which is an anaerobic environment suitable 
for C. perfringens growth and thus toxin production. There is no evidence that this has ever 
occurred in humans, but given the preexisting GI diseases often found in regions in most 
desperate need of HIV-1 vaccines, it is prudent to take as many precautions as possible. Because 
of this, C. perfringens strains with inactivation of both α-toxin and θ-toxin have been developed 
which has been shown to express SIV p27 and deliver viral antigen to the terminal ileum [182, 
183]. 
Since it has been shown that inactivating the cpe gene renders C. perfringens avirulent in 
the intestine [1], a vaccine against HIV-1 using cpe gene-deleted C. perfringens should be safe 
for use in humans. Furthermore, since the type A C. perfringens (used in this study) present in 
normal intestine flora are cpe-negative and reside predominantly in the large intestine there is no 
chance for the wild type cpe gene and other toxin genes to be reintroduced in our vaccine 
construct through recombination in vivo since the vast majority of recombinant C. perfringens 
should be lysed in the ileum before passage to the large intestine. 
Although there is no evidence for recombination of genetic material between food-
acquired C. perfringens and GI tract resident C. perfringens or other bacteria in the gut, there is 
the potential for a resistance gene to be transferred if included in a vaccine. In the course of the 
development of the α and  knock out  mutants, a C. perfringens strain expressing SIV Gag was 
created that lacks the antibiotic resistance gene [182]. Thus, future research with C. perfringens 
expressing HIV-1 proteins can be performed utilizing this new generation of C. perfringens with 
multiple safety mutations and lacking antibiotic resistance genes.  
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Therefore in this dissertation, the development of a novel heterologous prime boost 
vaccination strategy using recombinant C. perfringens expressing HIV-1 proteins and HIV-1 
VLPs is reported. It has been demonstrated that these vectors induce robust systemic as well as 
mucosal antigen specific cellular immune responses. Therefore these results present an 
alternative vaccination approach for generation of cellular immune responses against HIV-1 at 
mucosal sites of infection and merit further study of recombinant C. perfringens and VLPs as 
mucosal HIV-1 vaccine candidates. 
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2.0  SPECIFIC AIMS 
The mucosal sites such as the gastrointestinal (GI) tract are major targets for early HIV-1 
infection [18, 39]. Strong immune responses against HIV-1 at these sites may protect early 
infection. Thus an effective vaccine against HIV-1 should induce strong immune at the mucosal 
sites to prevent early HIV-1 infection. Mucosal vaccines represent an attractive approach for 
immunization against HIV-1 infections due to their importance in eliciting protective immune 
responses both at mucosal and systemic sites. Therefore a vaccine that can prevent virus 
transmission at mucosal surfaces by inducing strong mucosal immune responses at the site of 
infection would be an effective HIV-1 vaccine candidate. Oral immunization strategies have 
been shown to induce immune responses in the GI tract [137, 138], whereas nasal immunization 
strategies have been reported to induce immune responses in the respiratory and genitourinary 
tracts [136, 138]. Therefore, using these routes for immunization with HIV-1 vaccine candidates 
should enable the development of protective immune responses against HIV-1 at its major sites 
of primary infection.  
A vaccine containing the recombinant Clostridium perfringens expressing HIV-1 Gag has 
been designed to stimulate immunity in the GI tract with the expectation that the resulting 
immunity may be transferred to other mucosal sites such as vaginal and rectal tissue. It has been 
shown that recombinant clostridia are potent vehicles for delivering SIV-Gag to the lymphoid 
tissues of the GI tract [1]. Therefore I propose to use recombinant noncytotoxic (cytopathic gene 
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deleted) C. perfringens as a novel oral vaccine vehicle to deliver HIV-1 proteins in large 
quantities to the terminal ileum in order to induce strong mucosal immune responses against 
HIV-1. Orally administered HIV-1 antigens via C. perfringens will survive the low pH, bile salts 
and proteolytic enzymes of the stomach and GI tract and will be exposed to M cells in PPs which 
will induce strong mucosal immunity against the virus. Recombinant C. perfringens expressing 
HIV-1 proteins alone may not be enough to give strong, durable cellular and humoral immune 
responses. Therefore a prime/boost vaccine approach may elicit better and more effective 
immune responses [184]. Priming or boosting with another HIV-1 vaccine construct like virus 
like particles (VLPs) may elicit more effective mucosal immune responses. VLPs are non-
infectious virus particles and have become a promising candidate in the quest for a safe and 
effective vaccine against HIV-1/SIV [185, 186]. Therefore, combinations of intranasal delivered 
VLP and orally delivered recombinant Clostridium perfringens expressing HIV-1 proteins in 
different prime-boost vaccination approaches may elicit stronger mucosal immune responses 
than either vector alone since two independent mucosal compartments will be targeted by each 
vector which will lead to a better coverage of the mucosal immune inductive sites. Thus I 
hypothesize that the oral immunization of recombinant Clostridium perfringens expressing 
HIV-1 proteins and intranasal administration of HIV-1 VLP in a prime boost strategy will 
elicit strong mucosal immune responses against HIV-1. This hypothesis was addressed by the 
specific aims listed below.  
 
1. To construct and characterize the vaccine vectors; a recombinant C. perfringens 
expressing HIV-1 proteins and HIV-1 Virus like particles. Recombinant C. perfringens 
expressing HIV-1 proteins were constructed and expression of these proteins in vitro was 
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 2. To determine the ability of recombinant C. perfringens expressing HIV-1 proteins to 
induce DC maturation and its ability to prime HIV-1 specific T cell responses in 
vitro. Bone marrow derived dendritic cells were exposed to recombinant C. perfringens 
expressing HIV-1 proteins and expression of maturation markers on cell surface was 
monitored by flow cytometry. The antigen presentation function of BMDCs was assessed 
through ELISPOT assays by measuring HIV-1 Gag specific gamma interferon (IFN-γ) 
producing T cell responses following restimulation by vaccine-exposed BMDCs. 
 
3. To measure the mucosal HIV-1 specific cellular immune responses in mice after 
immunization with recombinant C. perfringens expressing HIV-1 proteins alone or 
along with HIV-1 VLPs in a prime boost strategy. Mice were immunized with 
recombinant C. perfringens expressing HIV-1 Gag along with optimized adjuvants either 
alone or in different prime-boost combinations with HIV-1 VLPs. HIV-1 Gag specific 
IFN-γ secreting T cells in the spleen, mesenteric lymph nodes, lamina propria( LP) and 
Peyer’s patches (PPs) of the immunized mice were detected by ELISPOT assays. 
Characterization of HIV Gag specific T cell responses was further evaluated by using 
CD4+ or CD8+ T cell depletion in all mucosal and systemic samples by ELISPOT assay. 
The functionality of HIV-1 Gag specific GI tract T cells responses in inductive and 
effector tissues was characterized with multi-color flow cytometry. In addition, HIV-1 
Gag specific humoral responses were assayed with ELISA. 
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3.0  CONSTRUCTION AND CHARACTERIZATION OF RECOMBINANT C. 
 PERFRINGENS EXPRESSING HIV-1 GENES AND HIV-1 VIRUS LIKE PARTICLES 
3.1 PREFACE 
The study described in this chapter was done by Poonam Poonam with technical help from Dr. 
Yue Chen and Sean McBurney. The construction of recombinants expressing HIV-1 Gag genes 
was done according to the methods previously described by Chen et al [1]. The PJRC200 
plasmid was a kind gift of Dr Bruce McClane of the University of Pittsburgh 
3.2 ABSTRACT 
An effective HIV-1 vaccine is necessary for preventing HIV-1 infection. Since most HIV-1 
infections are acquired via mucosal surfaces, an effective preventive vaccine against HIV-1 
should induce mucosal immunity as well as systemic immunity to prevent systemic infection 
from the mucosal surfaces. A noncytotoxic (enterotoxin gene deleted) Clostridium perfringens, a 
gram positive anaerobic bacterium, has been used in this study as a novel oral vaccine vehicle to 
deliver HIV-1 proteins in large quantities to the terminal ileum to induce strong mucosal and 
systemic immune responses. A recombinant shuttle plasmid (pJRC200) carrying HIV-1 genes 
was constructed by inserting the HIV-1-p24 or HIV-1-p55 genes in the place of the cytotoxic 
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region of the cpe gene which is under the control of the cpe promoter. When this recombinant 
plasmid was transformed into C. perfringen entertoxin (cpe) negative C. perfringens, large 
amounts of the viral protein were produced during sporulation of the C. perfringens, as 
determined by a semi-quantitative western blot analysis. These recombinant clostridia were then 
used in the vaccine approaches described in subsequent chapters. Also HIV-1 virus like particles 
(VLPs) were constructed and used as an intra nasal vaccine vector. The VLPs were obtained by 
transfection of COS cell lines with plasmid DNA encoding HIV-1 Ada strain gag/env genes. 
Supernatant was collected and then the VLPs were purified from these supernatants by 
ultracentrifugation. A western blot was performed to verify the expression of HIV-1 proteins in 
the VLPs. These result shows high expression of whole Gag or p24 proteins in sporulating media 
and amount of proteins produced are directly related to high % of spores of Clostridium 
perfringens. 
 
3.3 INTRODUCTION 
An effective vaccine against HIV-1/SIV must induce mucosal immunity to prevent early HIV-1 
infection. Because the gut is the major site of CD4+ T cell depletion and HIV-1 replication [157] 
and the mucosal layer of the gastrointestinal (GI) tract is naturally exposed to bacteria in the 
lumen, a bacterial vector provides an attractive vehicle. A number of efforts have been made to 
develop a vaccine that elicits a mucosal immune response against HIV-1. Clostridium 
perfringens has also been considered as a vehicle for antigen delivery to the GALT [1]. The 
ability for C. perfringens to naturally travel through the intestine, deliver protein to the vicinity 
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of PPs, and exit the host without colonizing or causing infection makes it an attractive vector for 
further exploration. A unique property of C. perfringens is the presence of a very highly active 
cpe promoter. The cpe promoter is activated only during sporulation [187, 188]. The bacterial 
protein expressed from the cpe promoter remains untouched by proteases and bile salts of the 
intestinal lumen presumably because expressed proteins are present in the cytoplasmic inclusion 
body. These properties make the cpe promoter and its natural regulation in C. perfringens an 
exquisite tool for expressing large amounts of protein that can be delivered intact in particulate 
form to the site of many PPs in the small intestine terminal ileum. Oral ingestion of C. 
perfringens not carrying the cpe gene may be considered safe for humans [189]. Therefore 
recombinant C. perfringens is now being developed as a vaccine vector against HIV-1. In 
addition to its ability to deliver intact protein to the mucosal surfaces of the GI tract, C. 
perfringens has the benefits of being an inexpensive vaccine vector that can be delivered orally 
without the requirement of needles. In this report we have shown construction of recombinant 
clostridia expressing high level of HIV-1 Gag protein and produced HIV-1 VLP. 
3.4 MATERIALS AND METHODS 
3.4.1 Construction of recombinant C. perfringens carrying HIV-1 Gag and envelope genes 
The construction of recombinant C. perfringens carrying HIV-1 Gag (p24 or p55) and Envelope 
(gp120 or gp140) were constructed in similar manner as described previously for SIV-p27 [1]. 
Briefly, the construction of  recombinant C. perfringens expressing these genes have been 
achieved using the pJRC200 plasmid, which contains cpe gene cassette including its promoter, 
 39 
open reading frame and downstream sequence [190]. For construction of recombinant plasmid 
containing HIV-1 Gag genes, the entire HIV-1-p24 or HIV-1-p55 ORF was amplified by PCR 
from a molecular clone of HIV-1 pNL4-3 with the primers p24 forward 
(TTCGAACCCATCGTGCAGAACATCCAG) and p24 reverse 
(CCTAAGGACAGCACGCGGGCCTTGTG) or p55 forward 
(TTCGAAATGGGCGCCCGCGCCAGCGTG) and p55 reverse 
(CCTAAGGATTGTGACGAGGGGTCGCTGCC), designed to contain either BstB1 or Bsu36I 
restriction site at the 5’ end of each primer (underlined). The resultant PCR products were then 
digested with these two enzymes and inserted into the plasmid pJRC200 [191] which was also 
digested with BstB1 and Bsu36I to remove most of the cpe ORF to get the recombinant pJRC200 
plasmids containing the p24 or p55 genes (cp24 or cp55). Similarly pJRC200 plasmids carrying 
HIV-1 envelope gene gp120 (cp120) and gp140 (cp140) (a gene segment encoding the 
transmembrane domain of gp41 in addition to the full length gp120 protein), were constructed. 
HIV-1 gp120 and gp140 genes were amplified from the full length clone of the HIV-1 isolate 
ADA. Primers pair for amplifying these genes were as follows: HIV-1-gp120 and gp140 F 
(GTTCGAAATGAAAGTGAAGGGGATCAGGAAGAA) and HIV-1-gp120 R 
(AGCTAAGCCTCTTTTTTCTCTCTGCACCAC) and HIV-1-gp140 R 
(AGCTAAGCATCCCTGCCTAACTCTATTTACTATAGAAAGTACAG). Then these 
plasmids were individually electroporated into a cpe negative strain of C. perfringens (C. 
perfringens strain ATCC 3624). 
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3.4.2 Bacterial growth conditions 
A vegetative culture of C. perfringens (non toxic C. perfringens strain ATCC 3624) was grown 
overnight at 37°C in FTG media (fluid thioglycolate broth) (Difco). A Modified Duncan-Strong 
medium (MDS) was used to obtain sporulating cultures of C. perfringens [192]. All media were 
supplemented with 10–20 ug of chloramphenicol per milliliter for growing transformants 
containing pJRC200- based plasmid constructs. The percentage of sporulating C. perfringens 
cells formed in MDS was determined by observation under a phase-contrast microscope. 
3.4.3 Transformation of C. perfringens with pJRC200- based plasmid constructs 
Electroporation was performed to introduce cp24/cp55/cp120/cp140 or the control pJRC200 into 
C. perfringens. Vegetative cultures of clostridia were grown at 37°C to late log phase in TGY 
broth (3% Trypticase, 2% glucose, 1% yeast extract, and 0.1% cysteine), washed twice with 
SMP buffer (270 mM sucrose, 1 mM MgCl2, and 7 mM Na2HPO4, pH 7.3), and then 
resuspended in 1 ml of SMP buffer. Then 400 microliters of those washed cells and plasmid 
DNA (5 ug) in 0.4 cm cuvette (Bio-Rad) were placed in a Bio-Rad Gene pulser set for 2.5 kV, 
200Ω and 25 μFD. After pulsing, 3 ml of warm (37°C) TGY broth was added and the mixture 
was incubated for 3 hours at 37°C. An aliquot of this mixture was placed on BHI agar (brain 
heart infusion agar) (Difco) plate containing 10 ug/ml of chloramphenicol. Those plates were 
incubated for 24 hours at 37°C in an anaerobic atmosphere, created using a BBL GasPak jar. 
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3.4.4 Western blot analysis 
The expression of HIV-1 Gag or Env proteins was confirmed in sporulating cultures of the 
transformed bacteria by a semi quantitative western blot. Recombinant C. perfringens were 
harvested, washed, and sonicated in PBS after culture in FTG or MDS media. Cells were then 
lysed and separated on a 15% SDS-PAGE gel. Protein was transferred to nitrocellulose 
membrane and incubated with anti-HIV-1 monoclonal antibody (from NIH AIDS Research and 
Reference Reagent Program) for an hour at room temperature. After washing, the membrance 
was incubated with horseradish peroxidase-conjugated goat anti-mouse antibody (Nordic 
Immunological Laboratories) for an hour. Protein bands were detected with SuperSignal West 
Pico Chemiluminescent Solution (Pierce). Blots were analyzed via densitometry using Quantity 
One software (Bio-Rad). 
3.4.5 Vaccine constructs 
The construction and purification of HIV VLPs has been developed in the Dr Ted Ross’s 
laboratory and described elsewhere [193]. Briefly, HIV-1 VLPs were obtained by transiently 
transfecting the monkey fibroblast cell line, COS, with a plasmid expressing Gag, Gag–Pol, VLP 
as described previously [193]. The culture supernatants of the transfected COS cells were 
collected and subjected to ultracentrifugation (100,000 g through 20% glycerol, w/v) for 4 hours 
at 4°C. The subsequent pellets were resuspended in PBS and overlaid onto 20–60% sucrose 
gradients (11 steps, 4% increments). Further ultracentrifugation was performed for 17 h at 
100,000 g at 4°C and eleven fractions (20–60%, 1 ml, weight per volume) were collected top to 
bottom from the gradient. The particles were precipitated with equal volumes of 20% 
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trichloroacetic acid (TCA) and subjected to SDS-PAGE and immunoblotting. The viral proteins 
were detected by a western blot. 
 
3.5 RESULTS 
3.5.1 Construction of a recombinant C. perfringens vaccine strain carrying HIV-1 Gag 
(p24 or p55) and HIV-1 envelope (gp120/gp140) genes  
A schematic representation of the construction of C. perfringens carrying HIV-1 p55 gene is 
shown in Figure 5. For construction of the recombinant vaccine strain, we used a C. 
perfringens/E. coli shuttle plasmid pJRC200, which contains the wild-type cpe gene. The 
pJRC200 was digested with restriction enzymes to remove the cpe cytotoxicity region, leaving 
the cpe promoter and a small amount of 5’ and 3’ sequences for transcription/translation 
efficiency and mRNA stabilization, respectively (Figure 5). The digested plasmid was then 
ligated with the p24/p55 ORF amplified from HIV-1 pNL4-3 isolate or gp120/gp140 ORF 
amplified from HIV-1 ADA isolate. The resulting plasmid was then introduced by 
electroporation into cpe-negative C. perfringens isolate ATCC3624.  
Using similar methods recombinant Clostridium perfringens carrying HIV-1 envelope 
gp120 or gp140 genes were constructed. For this purpose, HIV-1 gp120 and gp140 were 
amplified from full length HIV-1 isolate ADA. After the sequence was confirmed, these were 
cloned into pJRC20, the Clostridium perfringens shuttle plasmid. The recombinant pJRC200 
plasmid carrying HIV-1 gp120 or gp140 were subsequently electroporated into cpe negative C. 
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perfringens. Finally the protein expression of these two constructs was also verified by western 
blot. 
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Figure 5. Schematic representation of construction of recombinant clostridia expressing HIV-1 p55 
For construction of the recombinant vaccine a C. perfringens/E. coli shuttle plasmid pJRC200, which contains the wild-type cpe 
gene was used. The pJRC200 was digested with restriction enzymes to remove the cpe cytotoxicity region, leaving the cpe 
promoter region and a small amount of 5Vand 3Vsequences .The digested plasmid was then ligated with the HIV p24 or p55 
ORF amplified from HIV-1 Pnl4-3 isolate or from pIndieC11 isolate, resulting plasmid, named Cp-24 or Cp-p55 (Gag), was then 
introduced by electroporation into cpe-negative C. perfringens isolate ATCC3624.  
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3.5.2 Expression of the HIV-1 Gag and envelope proteins by the recombinant C. 
perfringens 
Recombinant C. perfringens carrying HIV-1 p24/p55 expression plasmids were grown overnight 
in MDS media were pelleted by centrifugation and cell lysates were prepared from these cell 
pellets by sonication. The expression of HIV-1 p24 or p55 by the sporulating recombinant 
clostridia was quantitated to be 40-50 ug of protein for both HIV-1 p24 and HIV-1 p55 per 
milliliter (about 1x107 – 1x 108 cells) of sporulating culture (Figure 6).  
Similarly recombinant C. perfringens carrying HIV-1 gp120/gp140 expression plasmids 
were analyzed for protein expression by a semi-quantitative western blot experiment. In contrast 
to C. perfringens carrying HIV-1 p24/p55, the recombinant clostridia expressing HIV-1 envelope 
genes (cp120/cp140) did not did not show any expression of HIV-1 envelope proteins in the 
western blots (data not shown).  
.
C
.
10
0n
g
25
ng
V
ec
to
r o
nl
y
C
p/
p2
4 
Sp
or
es
p55 Standards
A B
C
p/
p2
4 
sp
or
es
V
ec
to
r o
nl
y
27
0 
ng
90
 n
g
p55 Standards
HIV-p55 from pNL43
81 Kd
32 Kd
V
ec
to
r o
nl
y
C
p 
 c
lo
ne
 1
 
C
p 
cl
on
e 
2 
p55 standard
25
0 
ng
HIV p24 from pIndieC11 HIV-p24 from pNL43
81 Kd
32 Kd
81 Kd
32 Kd
.
.
10
0n
g
25
ng
V
ec
to
r o
nl
y
C
p/
p2
4 
Sp
or
es
C
p/
p2
4 
sp
or
es
V
ec
to
r o
nl
y
27
0 
ng
90
 n
g
V
ec
to
r o
nl
y
C
p 
 c
lo
ne
 1
 
C
p 
cl
on
e 
2 
25
0 
ng
 
Figure 6. Western blot analysis of recombinant C. perfringens expressing HIV-1 p24 from pIndie C (A),  
HIV-1 p24 ( B) or p55 from pNL4-3 (C) proteins.  
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3.5.3 Purification and expression of HIV-1 virus like particles 
HIV-1 virus-like particles (VLPs) were purified from the supernatants of transiently transfected 
cells by ultracentrifugation (20–60% sucrose gradient) and collected fractions were analyzed for 
particle composition and stability. Figure 7 shows the expression of HIV-1 Gag gene products in 
both the cell lysates and supernatant of COS-7 cells transfected with the plasmids encoding 
various HIV-1 proteins as described elsewhere [193].  
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Figure 7. (A) Schematic representation of the construction and purification of HIV-1 VLPs, (B) Western blot 
analysis of purified HIV-1 VLPs.  
Lane 1 is the whole cell lysates, lane 2 and 3 are the two different samples of the purified HIV-1 VLP showing p55, p41 and p24 
bands. 
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3.6 DISCUSSION 
The mucosa is the major natural route of HIV-1 transmission and infection, therefore generating 
HIV-1 specific strong responses at mucosal sites is very important in preventing HIV-1 
infections. Administration of antigens to mucosal surfaces might be the best method for inducing 
mucosal immune responses at local as well as distant sites such as lung and genital sites. 
Therefore an oral vaccine could trigger immune responses at mucosal sites, which could lead to 
protection against virus challenge. Since the mucosal layer of the gastrointestinal tract (GI) is 
naturally exposed to Clostridium perfringens in the lumen, these bacteria could present as a 
vehicle to deliver HIV-1 proteins in a large quantity to the gut-associated lymphoid tissue 
(GALT) to stimulate mucosal immunity against HIV-1. We have shown that recombinant C. 
perfringens expresses high amount of SIV protein in vitro, and we have also shown the evidence 
of a recombinant C. perfringens vaccine construct that produced a high level of HIV-1 proteins 
in vitro under sporulating conditions. Expression of the HIV-1 p55 protein expressed by 
recombinant clostridia was quantitated to be approximately 40-50μg/ml sporulated bacterial 
culture (108 cfu) which is similar to recombinant clostridia expressing SIV p27 reported earlier 
[1]. Interestingly, the p55 gene is twofold larger in size than p24 or p27, yet similar level of 
expression was obtained, indicating that clostridia is able to handle longer gene inserts for 
expression purpose. The cpe promoter driven expression of protein accounts for about 15 % of 
the total C. perfringens proteins and this is one of the highest known to be reported in a bacterial 
vaccine construct. This expression rate is higher when compared with bacteria commonly used 
for protein expression [194]. In one example of an efficient expression system, E. coli expressed 
human metallothionein 2A as 10-15% of total protein [195]. It has been shown that upon oral 
feeding, the recombinant C. perfringens vaccine carrying SIV p27 construct delivered a large 
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amount of intact p27 fusion protein to the terminal ileum, indicating p27 protein present in the 
inclusion body is protected from the harsh environment of the GI tract [1]. Oral delivery of 
inclusion bodies carrying viral antigens have been shown to induce both systemic and mucosal 
immune responses without any adjuvant [196]. Therefore, the delivery of intact HIV-1 antigens 
to the GALT by the recombinant C. perfringens should induce strong antigen specific mucosal 
immune responses.  
The failure to obtain recombinant C. perfringens expressing HIV-1 envelope proteins 
may be due to numerous factors. Since these envelope proteins are highly glycosylated and the 
bacterium lacks the capacity for glycosylation, these recombinant clostridia might not be able to 
express the non glycosylated form of these proteins. It is also possible that sequences present in 
HIV-1 envelope may be toxic for bacteria or have bactericidal effect. Therefore the lack of 
expression of HIV-1 envelope by recombinant C. perfringens could be due to lack of 
glycosylation of these proteins and/or bacteriotoxic properties of these proteins. 
Overall, a novel C. perfringens based vector expressing HIV-1 Gag was successfully 
constructed. This recombinant C. perfringens also expressed a large amount of HIV-1 Gag under 
sporulating conditions, that are prevalent in the GI tract and thus presents an attractive mucosal 
vaccine vector against HIV-1 that can deliver large amounts of HIV-1 proteins to the immune 
cells present in the GI tract. 
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4.0  DETERMINE THE ABILITY OF RECOMBINANT C. PERFRINGENS 
EXPRESSING HIV-1 PROTEINS TO INDUCE DENDRITIC CELL MATURATION 
AND ANTIGEN PRESENTATION TO T CELLS 
4.1 PREFACE 
This study was performed by Poonam Poonam. Technical help was received from Ruth Helmus. 
4.2 ABSTRACT 
Dendritic cells (DCs) are present at the sites of antigen exposure and at the inductive mucosal 
sites such as the gastrointestinal (GI) tract. In this study, the ability of a recombinant C. 
perfringens expressing HIV-1 Gag (Cp-Gag) to stimulate T cell mediated immune responses in 
vitro was investigated. Freshly isolated murine bone marrow derived dendritic cells (BMDCs) 
upon exposure to Cp-Gag, up-regulated maturation markers on their cell surface. Furthermore, 
these mature BMDCs stimulated HIV-1 Gag specific IFN-γ production by immune T cells, 
demonstrating that the HIV-1 Gag antigen was efficiently delivered to, processed by, and 
presented on MHC molecules by BMDCs. These findings suggest that HIV-1 Gag from 
recombinant C. perfringens expressing HIV-1 Gag when delivered to DCs enable these DCs to 
present HIV-1 Gag epitopes to T cells. 
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4.3 INTRODUCTION 
Dendritic cells (DCs) are potent antigen-presenting cells and are an important component of the 
immune response to pathogens. On exposure to pathogens, DCs mature by up-regulation of 
costimulatory and maturation markers on their surfaces enabling them to prime and activate 
antigen specific T cells. DCs also possess the unique ability to present exogenously acquired 
antigens that are normally loaded onto MHC class II molecules in the context of MHC class I, 
which is necessary for inducing a CD8+ cytotoxic T lymphocyte (CTL) response [197, 198]. The 
CD8+ CTL response to HIV-1 appears essential for limiting viral infection, as displayed by 
numerous studies of both systemic and mucosal immune responses to HIV-1/SIV [60]. Thus, to 
generate an effective anti-SIV CD8+ CTL response, a vaccine must induce DCs to present HIV-1 
antigen to CD8+ T cells and induce priming of anti-HIV-1 CD8+ CTLs. 
A study was initiated to determine whether DCs exposed to recombinant C. perfringens 
expressing HIV-1 Gag proteins (Cp-Gag) can prime and activate antigen specific T cells. To 
study the effectiveness of recombinant to induce a DC-mediated immune response, the 
functional capacity of T cell stimulatory capacity of DCs exposed to Cp-Gag were investigated. 
The effects of Cp-Gag were examined using murine bone marrow-derived DCs (BMDCs). 
Murine BMDCs were exposed to Cp-Gag and examined for surface expression of maturation 
markers and cytokine production. The function of DCs was also assessed by co-culture of 
BMDCs with HIV-1 Gag specific T cells and detection of IFN-γ production by these T cells 
using an ELISPOT assay. These results demonstrate that Cp-Gag can efficiently stimulate a DC-
mediated Gag-specific immune response in vitro, which suggests that in vivo immunization 
might result in HIV-1 Gag specific cellular immune responses.  
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4.4 MATERIAL AND METHODS 
4.4.1 Animals 
6-8 weeks old female BALB/c mice were purchased from Charles Rivers Laboratories, Inc. and 
housed in a pathogen-free facility in accordance with the University of Pittsburgh Institutional 
Animal Care and Use Committee. 
4.4.2 Antibodies 
FITC-α-CD40 (clone L3T4), FITC-α-CD80 (16-10A1), FITC-α-CD86 (GL1), R-PE-α-CD8a 
(53-6.7), R-PE-α-CD11c (HL3), unconjugated α-I-Ad (AMS-32.1), and unconjugated α-H-2Dd 
(34-5-8S) antibodies against mouse antigens and α-human CD3 (UCHT1) were purchased from 
BD Pharmingen. Isotype control antibodies were purchased from the same manufacturers 
according to the fluorescent conjugate used. 
4.4.3 Construction of recombinant C. perfringens 
Construction of recombinant Clostridium perfringens expressing HIV-1 Gag protein has been 
described in aim 1. Expression of HIV-1 Gag was confirmed in sporulating cultures of the 
recombinant clostridia by western blot. 
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4.4.4 Murine bone marrow derived dendritic cells 
Mouse bone marrow-derived dendritic cells (BMDCs) were prepared as described previously [1]. 
Briefly, bone marrow cells flushed from the femurs and tibias of mice were seeded and cultured 
at 8 x 106 cells in 6-well plate wells in 4 ml RPMI 1640 containing 10% heat-inactivated fetal 
bovine serum, 1% L-glutamine, 1% sodium pyruvate, 1% nonessential amino acids, 1% 
penicillin-streptomycin, 0.025 M 2-mercaptoethanol, and 4 ng/ml of both GM-CSF and IL-4. At 
day 2, non adherent cells were removed and 50% of the supernatant was replaced with fresh 
cytokine-containing medium. The cells (40-60% CD11c-positive) were then used after culture 
for 5-6 days. 
4.4.5 Maturation of BMDCs by recombinant C. perfringens expressing HIV-1 Gag 
protein  
Freshly prepared BMDCs (1-2x106 cells per 4ml) were incubated with ~2x105/ml sporulated, C. 
perfringens expressing Gag (Cp-Gag), empty vector C. perfringens control, purified Gag protein 
at a concentration equivalent to that expressed by the recombinant clostridia, and 0.5 μg/ml LPS.  
The stimulation media were removed after 2 hours via washing and centrifugation and the 
BMDCs were returned to culture for 22 additional hours. Culture supernatants were then 
collected and stored at -20°C, whereas the cells were harvested and utilized for further assays.  
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4.4.6 Flow cytometric analysis of BMDCs 
For flow cytometric analysis, DCs were surface stained for CD11c, CD40, CD80, CD86, and 
MHC class II (I-Ad) at 4°C. After staining, all cells were fixed using 1% paraformaldehyde, and 
data were collected using a Coulter Epics XL-MCL flow cytometer.  
4.4.7 ELISPOT assay 
The detection of antigen specific interferon-gamma (IFN-γ) producing cells was performed using 
mouse IFN-γ ELISPOT Kits from Mabtech. HIV-1-Gag specific splenocytes (2x105 cells per 
well) were placed at 37°C for 1 hours, and then BMDCs exposed to Cp-Gag or control C. 
perfringens were added to ELISPOT plate wells at a 1:1 or 1:5 – splenocytes: DC ratio, 
respectively, in a final volume of 200 ul of ELISPOT media ( RPMI-1640 with 10% FBS, 1% 
penicillin/streptomycin, 0.1 mM non-essential amino acids, 2 mM L-glutamine, 10 mM HEPES, 
and 1 mM sodium pyruvate). DMSO equivalent to the amount present in the peptide pools was 
also added as background control to the each well. The treatments for all samples were plated in 
quadruplates. The cells were then incubated at 37°C, 5% CO2 atmosphere for 24h. After 
incubation cells were washed away and ELISPOT plates were assayed for IFN-γ producing cells 
as per manufacturer’s protocol (MABTECH ELISPOTplus for mouse IFN-γ) kit. The number of 
spot forming cells (SFC) was counted on an ELISPOT reader. The results are expressed as 
number of spots per 106 cells in stimulated wells minus the number in unstimulated wells. 
For HIV-1Gag specific splenocytes; mice were immunized subcutaneously with 10 ug of 
HIV-1-Gag protein/per mouse along with complete freund’s adjuvant. Mice were boosted once 
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at 10 days with 5 ug of HIV-1 Gag along with incomplete freund’s adjuvant. Finally mice were 
sacrificed at day 14 after a final boost and splenocytes were used in assay. 
4.5 RESULTS  
4.5.1 Maturation of BMDCs exposed to C. perfringens expressing HIV-1 Gag 
An in vitro experiment was performed to evaluate the interactions of recombinant C. perfringens 
expressing HIV-1 Gag (Cp-Gag) with bone marrow derived dendritic cells (BMDCs). In this 
experiment, it was determined whether BMDC can uptake and process HIV-1 Gag expressed by 
the recombinant C. perfringens. Immature BMDCs were pulsed for 2 hours with lysates of Cp-
Gag or LPS as a positive control and untreated BMDCs served as a negative control. BMDCs 
were then washed to remove all bacteria and incubated overnight in culture medium with 
antibiotics. Following overnight culture, BMDCs were then analyzed for the expression of co-
stimulatory molecules - CD40, CD80, CD86, and a DC marker - anti-CD11c. Flow cytometry 
was performed to determine the intensity of maturation markers on the surface of BMDCs. 
The results indicate that the percentage of cells expressing CD40, CD80 and CD86 in 
BMDCs co-cultured with Cp-Gag were very similar to those observed in control LPS-treated 
BMDCs and higher than control BMDCs cultured in media alone. Furthermore, the mean 
fluorescence intensity (MFI) of the CD40, CD80 and CD86 expressed by BMDCs treated with 
Cp-Gag were significantly higher than the group where BMDC were not treated with any 
vaccine (p<0.05).  Furthermore, BMDC showed higher expression of maturation markers on DC 
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when treated with C. perfringens containing empty vector or LPS (Figure 8). These results 
demonstrate that recombinant clostridia were able to induce maturation of BMDCs. 
 
Figure 8. Expression of maturation markers on BMDCs in response to C. perfringens expressing HIV Gag 
(Cp-Gag). 
BMDCs were cultured with Cp-Gag, empty vector control (Cp), LPS or BMDC were used without any treatment. Representative 
figures  from 2 independent experiments show  average mean fluorescence intensity of expression of maturation markers 
CD40, CD86 and CD80 on BMDC in response to stimuli as determined by flow cytometry. For statistical analysis p values were 
determined by Student’s t-test against untreated cells. *p<0.05. 
 
4.5.2 Functional capacity of BMDCs exposed to Cp-Gag 
The functional capacity of BMDCs exposed to Cp-Gag to process and present antigens to T cells 
was assessed. In this experiment, the BMDCs exposed to Cp-Gag were used to restimulate HIV-
1 Gag specific mouse splenocytes and IFN-γ secretion by these cells was detected by an 
ELISPOT assay. 
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Figure 9. HIV-1 specific IFN-gamma secretion by splenocytes co cultured with BMDCs exposed to Cp-Gag or 
control C. perfringens as measured by an ELISPOT assay. 
HIV-1 Gag specific murine splenocytes were stimulated with BMDC treated with Cp-Gag or Cp-empty vector. Two 
different ratios 1:1 and 5:1 of Splenocytes:BMDC were used in this experiment. IFN-γ ELISPOT results indicate 
data from 2 independent experiments. Error bars indicate standard error of the mean of samples assayed in triplicate. 
p-value determined by Student’s t-test.   
 
 
BMDCs exposed to lysates of Cp-Gag stimulated IFN-γ production by HIV-1 Gag 
specific splenocytes, indicating that the BMDCs indeed displayed HIV-1 Gag epitopes on MHC 
molecules and were capable of stimulating an immune response against Gag (Figure 9). The 
IFN-γ ELISPOT response stimulated by BMDC treated with Cp-Gag was about 12 times that 
stimulated by BMDCs exposed to control C. perfringens. It should be noted that the low 
background IFN-γ response detected by ELISPOT in wells containing BMDCs alone was similar 
regardless of whether BMDCs were treated with Cp-Gag or the control C. perfringens. These 
data demonstrate that the recombinant clostridia expressing HIV-1 Gag delivered HIV-1 Gag 
protein to BMDCs for efficient presentation to and stimulation of antigen specific T cells. 
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4.6 DISCUSSION 
The goal of this in vitro study was to determine whether Cp-Gag exposed DCs can induce an 
immune response against HIV-1 Gag. It has been previously shown that the bacteria based 
vaccines interact with DCs as shown in the case of L. monocytogenes which can stimulate 
cytotoxicity against antigen-specific target cells in vitro [115]. The present study investigated the 
phenotype and functionality of murine BMDCs following exposure to Cp-Gag. Upon exposure 
to Cp-Gag, BMDCs showed an increased surface expression of CD80, CD86, and CD40 when 
compared to BMDCs exposed to Gag protein alone. However BMDCs exposed to control 
bacteria carrying an empty expression vector also displayed increased expression of the 
maturation markers, as is expected due to the presence of peptidoglycan in the C. perfringens 
outer membrane. The splenocytes cultured with BMDC exposed to Cp-Gag showed at least 10-
fold higher antigen specific IFN-γ production that when cultured with BMDCs exposed to 
control C. perfringens. Overall this in vitro study demonstrated maturation of BMDCs following 
exposure to recombinant clostridia. It also demonstrated that these BMDCs can efficiently 
present antigen to antigen specific T cells. These results suggest that the DCs exposed to Cp-Gag 
have the potential to prime or activate antigen specific T cells to form a productive immune 
response in vivo. 
In a related study, freshly isolated Peyer’s patches DC (PPDCs) were exposed to 
recombinant C. perfringens expressing SIV p27 (Cp-p27) and up regulation of maturation 
markers and production of pro-inflammatory cytokines by the PPDCs were observed (personal 
communication, Ruth Helmus). These results indicated that DCs isolated from PPs could also 
mature upon interaction with recombinant clostridia expressed antigen and stimulate antigen 
specific cellular immune cells which suggests that HIV-1 antigen specific immunity could be 
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generated in vivo via delivery of HIV-1 proteins to PPDCs using recombinant clostridia. In 
addition, it was observed that unlike other bacterial and viral-based vectors, C. perfringens does 
not invade GI cells and therefore does not appear to present its antigens through the classical 
MHC class I pathway. However, it has been seen that DCs can alternatively process exogenous 
antigens and present antigens through the MHC class I pathway by a phenomena know as cross-
presentation [199, 200]. Because DCs in PPs have been shown to take up SIV p27 protein 
expressed by the recombinant C. perfringens, it is expected that the recombinant clostridia 
expressing HIV-1 proteins will induce both cellular and mucosal immune responses. 
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5.0  INDUCTION OF CELLULAR IMMUNE RESPONSES IN THE GUT MUCOSA 
AGAINST HIV-1 USING A COMBINATION OF RECOMBINANT CLOSTRIDIUM 
PERFRINGENS AND VIRUS LIKE PARTICLES 
5.1 PREFACE 
This chapter is adapted from a manuscript in preparation. This experiment was accomplished 
with the technical assistance of Ruth Helmus, Lori Caruso, Dr Yue Chen and Dr Cheng- Li Shen 
in vaccine administration, sample collection and processing. Flow cytometry was performed with 
the assistance of Luann Borowski. Dr. Ted M. Ross provided guidance for CpG ODN sequence 
selection. LT (R192G) or mLT was a kind gift of Dr. John Clemens. The antibodies against CD3, 
CD4 and CD8 were generous gift from Dr Rosemary Hoffman, of the University of Pittsburgh. 
Statistical help was provided by Dr. Patrick Tarwater. Portions of this work were presented at the 
AIDS Vaccine Conference 2006 (Development of a mucosal vaccine strategy against HIV-1 
using Virus like particles and recombinant Clostridium perfringens expressing HIV-1 proteins. 
Poonam, P, Chen, Y, McBurney, SP, Ross, TM, and Gupta, P) and at the 2008 Keystone 
Symposia on HIV-1 Vaccines (Induction of Polyfunctional T cells in the Gut Mucosa against 
HIV-1 using a Combination of Recombinant Clostridium perfringens and Virus like Particles. 
Poonam, P, Helmus R, Chen, Y, McBurney, SP, Ross, TM, and Gupta, P). 
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5.2 ABSTRACT 
The gastrointestinal tract is a major mucosal target of early HIV-1 infection [37]. Recombinant 
Clostridium perfringens has been shown to deliver SIV/HIV-1 proteins in large quantities to the 
terminal ileum in order to induce strong mucosal immune responses. Virus like particles (VLPs) 
has been shown to induce strong mucosal responses when delivered intranasally [141]. Therefore 
a mucosal immunization strategy using C. perfringens and VLPs should be able to induce potent 
immune responses against HIV-1 in the gastrointestinal (GI) tract and other mucosal tissues. 
Cellular immune responses play a central role in HIV-1 replication. Therefore, the ability to elicit 
potent cellular immune responses has become a priority for HIV-1 vaccine candidates. The 
effectiveness of an immunization strategy against HIV-1 can be measured by its capacity to 
induce HIV-1 specific CD4+ and CD8+ T cells that can produce IL-2 ,TNF-α and IFN-γ. Also the 
cytotoxic function of antigen specific CD8+ T cells is important for virus clearance during HIV-1 
infection. Therefore in this study HIV-1 Gag specific cellular immune responses induced by 
recombinant C. perfringens expressing HIV-1 Gag (Cp-Gag) and VLPs were evaluated. HIV-1 
specific mucosal immune responses in both the effector and inductive sites of the GI tract were 
significantly higher in mice immunized using recombinant Cp-Gag and VLPs in heterologous 
prime-boost approaches compared to mice immunized with either Cp-Gag or VLPs alone. These 
groups also had higher proportions of HIV-1 specific multifunctional T cells. However no 
significant HIV-1 specific humoral immune responses were detected in the mucosal or systemic 
compartments of the immunized mice. Mucosal immunization with a combination of Cp-Gag 
and VLPs was successfully able to prime GI tract mucosal immune responses against HIV-1, 
which may be important to counter HIV-1 infection at the gut at the initial stages of HIV-1 
infection. 
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5.3 INTRODUCTION 
Heterosexual transmission accounts for most of the worldwide spread of HIV-1 infection and 
mucosal sites such as the gastrointestinal (GI) tract are a major target for early HIV-1 infection. 
Therefore strong immune responses against HIV-1 at the mucosal sites may protect against early 
infection. Thus an effective vaccine against HIV-1 must induce mucosal immunity to prevent 
primary infection at the mucosal surfaces of the genital organs and the GI tract. The various sites 
of the mucosal immune system are interconnected and show a lot of similarities in overall 
mucosa structure [132]. Therefore immunization of the intestinal mucosal surface could also 
sensitize other mucosal surfaces at remote sites, namely genital surfaces, and induce both 
mucosal and systemic immune responses [201]. Mucosal vaccines using oral or nasal routes 
represent an attractive approach for immunization against HIV-1 infections due to their 
importance in eliciting protective immune responses both at mucosal and systemic sites; and also 
due to their ease of administration. Therefore, combining both of these routes for immunization 
with HIV-1 vaccine candidates should enable the development of protective immune responses 
against HIV-1 at its major sites of primary infection. 
Neutralizing antibodies have shown the ability to block HIV-1 infection [202], but they 
are difficult to generate. However, cellular immunity plays a critical role in controlling acute 
infection and maintaining low viral set point. Therefore, protective antiviral cytotoxic T 
lymphocytes (CTLs), particularly in the mucosal compartment, should be a major component of 
any immune response induced by an effective vaccine against HIV-1. While inducing cellular 
immunity at mucosal sites is important for HIV-1 vaccines, which generally are measured by 
HIV-1 specific IFN-γ secreting T cells; the functionality of immune response induced against 
HIV-1 also affects the outcome of infection [98]. Generally, functionality is measured by 
 61 
multifunctional T cells that make two or more cytokines on an individual cell basis and these 
have been associated with protection in vaccines trials against HIV-1 infection. HIV-1-infected 
long term non-progressors (LTNP) preferentially maintain HIV-1 specific T cells that produce 
multiple effector molecules like IL-2/TNF-α/IFN-γ and cytotoxic factors such as CD107a in the 
same effector cell termed as a multifunctional T cell [203]. However, the information of the 
multifunctionality of the T cells of the GI tract during HIV-1 infection is limited [101, 204]. It is 
expected that not just the level of response but also the quality of immunity, including 
multifunctional CD8+ T cells, in the mucosal tissues will relate directly to the outcome of 
infection or effectiveness of vaccine-induced immune responses [205]. Thus, examining the 
functional cellular responses in mucosal tissues such as the GI tract may provide correlations 
between control of HIV-1 infection and immunity, either natural or vaccine-induced. 
The mucosal layer of the GI tract is naturally exposed to bacteria in the lumen; therefore 
a bacterial vector provides an attractive delivery vehicle for HIV-1 vaccine. Clostridium 
perfringens was selected as a novel vaccine vector, because the unique characteristics of C. 
perfringens make it an attractive model for the development of a mucosal vaccine against HIV-1 
[1]. Most importantly, it provides a highly efficient inducible promoter, which has been shown to 
produce large amounts of target protein in the GI tract, where most of the body’s lymphocytes 
are located. Therefore C. perfringens derived vectors can be potent vehicles to deliver 
immunogens to the lymphoid tissues of the GI tract and may stimulate strong mucosal immune 
responses.  
Intranasal immunization with virus-like particle vaccines (VLPs) provides an alternative 
approach to induce mucosal immunity. VLPs, or pseudovirions, can be defined as self-
assembling, non-replicating, non-pathogenic, genome less particles that are similar in size and 
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conformation to intact virions. These immunogens can be administered as purified particles or as 
DNA plasmids expressing the viral proteins to form VLPs in vivo [139]. Several successful VLP 
vaccines have been developed and tested in human trials attesting to the efficacy of HIV-1 VLPs 
as a promising HIV-1 vaccine candidate [141, 142]. Intranasal delivery of VLPs have been 
shown as an effective vaccine to  induce strong immune responses at mucosal and systemic sites 
and requires lower doses of antigen than oral delivery [141].  
Efforts to develop a vaccine that elicits a mucosal immune response against HIV-1 have 
not been very successful due to the complex nature of mucosal surfaces and induction of immune 
tolerance. Adjuvants have been used in mucosal immunizations to overcome immune tolerance. 
Bacterial toxins, such as the mutated form of heat labile E. coli enterotoxins (mLT) and synthetic 
oligodeoxynucleotides (ODN) containing immunostimulatory CpG motifs (CpG ODN) are 
potent mucosal adjuvants and have been commonly used in animal models [169]. The safety of 
these adjuvants has been demonstrated in mice, nonhuman primates and humans [48]. The mLT 
has been used in many studies to enhance Th2 type immune response and CpG-ODN has shown 
to enhance adaptive Th1 humoral and cellular immune responses in mice and primates [169, 
170]. Therefore mLT and CpG-ODN adjuvants were used in the mucosal immunization 
strategies to overcome immune tolerance and generate strong mucosal immune responses.  
In this study a novel mucosal immunization strategy against HIV-1 using recombinant C. 
perfringens and HIV-1 VLPs to generate robust mucosal immune responses against HIV-1-Gag 
was developed. The results indicate that heterologous prime-boost immunization with oral 
administration of recombinant C. perfringens expressing HIV-1 Gag and intranasal 
administration of HIV-1 VLPs induce strong antigen specific T cell responses at both mucosal 
and systemic sites that are targets of early HIV-1 infection. 
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5.4 MATERIALS AND METHODS 
5.4.1 Animals 
6-8 weeks old female BALB/c mice were purchased from Charles Rivers Laboratories, Inc. and 
housed in a pathogen-free facility in accordance with the University of Pittsburgh Institutional 
Animal Care and Use Committee. 
5.4.2 Vaccine constructs 
The construction of recombinant C. perfringens expressing HIV-1-Gag proteins and VLP has 
been described in the chapter 3.  
5.4.3 Immunization of animals 
The animals were immunized orally by gavages with 150 ug of sporulating C. perfringens 
expressing HIV-1-Gag (oral) and intranasally with 10 ug of HIV-1 VLPs. The interval between 
successive immunizations was 3 weeks and animals were sacrificed 2 weeks after the final 
booster immunization. The animals were not fasted or ph neutralized before oral immunization. 
All procedures used in this study complied with federal guidelines and University of Pittsburgh 
Institutional Animal Care and Use Committee. 
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5.4.4 Mucosal Adjuvants 
Whole inactivated cholera toxin (CT), cysteine-phosphate-guanine oligodinucleotides (CpG 
ODNs) and mutant E. coli heat-labile toxin (mLT) were used as oral adjuvants in this study. CT 
and HPLC-purified S-thiolated CpG ODNs were purchased from Sigma. The CpG ODN 
sequences were: CpG-A=TCCATGACGTTCCTGACGTT; CpG-
B=TGACTGTGAACGTTCGAGATGA. The mLT was provided by Dr. John D. Clements and 
was reconstituted to 1 mg/ml in sterile water. 
5.4.5 Isolation of Lymphocytes from Spleen, Mesenteric Lymph Nodes, Peyer’s Patches 
and Lamina propria 
Mice were sacrificed 14 days after final immunization and spleens, mesenteric lymph nodes 
(MLN), and small intestines were removed. Blood samples were collected via heart puncture. 
Vaginal wash was collected via washing with PBS containing protease inhibitor and stored at -
70°C. Serum was separated from blood and was stored at -70C. Spleens were gently crushed 
with glass stoppers to release splenocytes, while the red blood cells were lysed with RBS lysing 
buffer. MLN tissues were gently crushed using glass stoppers to release the cells. Intestinal cells 
were isolated as described elsewhere with few modifications [206]. Briefly, the intestines were 
first rinsed with sterile PBS. Peyer’s patches (PP) were then carefully removed from the 
intestinal tissue by first removal of epithelial cells through incubation at 37C in EDTA-DTE 
solution [(PBS containing 10% bovine growth serum (HyClone), 1 mM EDTA, and 1 mM 
dithioerythritol( DTE)], and then PPs cells were released through incubation with collagenase 
solution (RPMI 1640 containing 10% fetal bovine serum and 1 mg/ml collagenase D) at 37C 
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followed by gentle crushing. The released PP cells were subsequently passed through a nylon 
mesh, spun down and washed with 2% cold RPMI. To isolate lamina propria (LP) cells, the 
remaining intestinal tissues were cut open longitudinally and made into 0.5-1cm pieces. The 
epithelial cells were removed through incubation with EDTA-DTE solution and then the tissue 
pieces were treated with collagenase solution for 30 minutes. Collagenase-treated pieces were 
gently crushed, and then released cells were subsequently passed through a nylon mesh, spun 
down and kept on ice in serum-containing medium. Remaining tissue pieces were returned to 
fresh collagenase solution for additional stirring at 37C and cell isolation. When all tissue pieces 
were digested, cells were washed and the cell pellet was resuspended in 12 ml ice-cold 40% 
isotonic Percoll in PBS, and then 4 ml of cell suspension was distributed equally into three15 ml 
tubes. Each 4 ml cell suspension was then underlayed with 100 % ice-cold isotonic Percoll. 
Tubes were then centrifuged at 1700 rpm with no brake at 4°C for 20 minutes. The resulting 
interface was harvested and diluted ≥10-times into fresh RPMI containing serum, and these LP 
lymphocytes were spun down for 10 minutes with centrifugation at 4°C at 1500 rpm. These 
single cell suspensions were then used for evaluating HIV-1 specific T cell responses by IFN-γ 
ELISPOT and flow cytometry assays. 
5.4.6 ELISPOT assay 
The detection of antigen specific interferon-gamma (IFN-γ) producing cells was performed using 
mouse IFN-γ ELISPOT Kits from Mabtech. Lymphocytes from spleen, MLN, PPs and LP 
tissues were used in this assay. Freshly isolated lymphocytes (2x105 cells/well) were placed on 
activated ELISPOT plates. These cells were stimulated (in triplicates) with 5 ug/ml/peptide pools 
of HIV-1 Consensus Subtype B Gag 15-mer peptides overlapping by 11 amino acids (NIH AIDS 
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Research and Reference Reagent Program). A background control; DMSO equivalent to that in 
the peptide pools was also added to each well. The treatments for all samples were plated in 
triplicate, except in case of low yields specifically for LP; in that case duplicate samples were 
used. The cells were then incubated at 37°C, 5% CO2 atmosphere for 24 hours. After incubation, 
the cells were washed away and ELISPOT plates were assayed for IFN-γ producing cells as per 
the manufacturer’s protocol (MABTECH ELISPOTplus for mouse IFN-γ). The number of spot 
forming cells (SFC) was counted on an ELISPOT reader. The results are expressed as number of 
spots per 106 cells in stimulated wells minus the number in non stimulated wells. 
5.4.7 ELISA to detect systemic and mucosal anti-HIV-1 antibodies  
96 well ELISA plates were coated with HIV-1 p24 protein (NIH AIDS Research and Reference 
Reagent Program) overnight. Then serial dilutions of serum or undiluted samples of fecal 
extracts, vaginal washes, or intestinal washes were made and placed in the wells. These plates 
were then incubated at room temperature for 2 hours (serum) or at 4°C overnight (fecal extracts, 
vaginal washes, and intestinal washes). Plates were washed, and AKP conjugated α-mouse IgG, 
IgG1 or IgG2a antibody or biotin-conjugated α-mouse IgA antibody (BD Biosciences) were 
placed in the appropriate wells for 1 hour at room temperature. For IgA detection, plates were 
washed and a secondary AKP-conjugated streptavidin (Sigma) was then incubated in appropriate 
wells for 30 minutes at room temperature. 4-nitrophenyl phosphate disodium salt hexahydrate 
(Sigma) was used to detect p24-specific antibody, and optical density was read on a plate reader 
at 405nm. Background values from negative control wells on each plate were subtracted.  
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5.4.8 T cell subpopulation depletion and enrichment 
To further identify the IFN-γ secreting specific T cell subset, either CD4 or CD8 depletion was 
performed. Single cell suspensions were prepared from freshly harvested LP, PPs, MLN and 
spleen tissues. The red blood cells were removed by using RBC lysing buffer. Mouse anti CD4 
(clone L3T4) or CD8 (clone Ly-2) microbead kits (Miltenyi Biotech) were used to enrich for 
CD4- or CD8- T cells, respectively. For CD4+ or CD8+ T cell depletion, cell suspensions were 
magnetically labeled with either CD4 or CD8a microBeads. After 15 minutes incubation on ice, 
the cell suspensions were loaded on a MACS® Column which was then placed in a magnetic 
field. The magnetically labeled cells were retained in the column. The unlabeled cells were 
passed through, and collected as the cell fraction that is depleted of either CD8+ or CD4+ T cells. 
These depleted cell populations were then used in the ELISPOT or flow assay along with the 
total, non separated T cells. The purity of the recovered cells was confirmed by flow cytometry 
analysis and was routinely greater than 95%.  
5.4.9 Surface and intracellular cytokine staining 
FITC-anti-CD107a (clone 1D4B), R-PE-anti-CD8 (clone 53-6.7), APC-anti-IL-2 (clone JES6-
5H4), PE-Cy7-anti-IFN-γ (clone XMG1.2), Biotin-anti-TNF-α (clone MP6-XT3), and APC-
Cy7-streptavidin were purchased from BD Pharmingen. PE-Cy5-anti-CD3 (clone 145-2C11) was 
purchased from BioLegend. Isotype control antibodies were purchased from the same 
manufacturers according to the fluorescent conjugate used. A total of 0.5 -2x106 freshly isolated 
cells were stimulated with 5 ug/ml of HIV-1-B Gag peptide pool in presence of 3 uM monensin 
and 5 ug/ml of brefeldin A in 200 ul growth media (DMEM with 10% fetal calf serum, 1 mM 
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sodium pyruvate, 2 mM L-glutamine, 0.025 M 2-Mercaptoethanol, and 1.25 mM HEPES). FITC 
conjugated antibody against CD107a (clone 1D4B), was also added in each well and the cells 
were incubated at 37°C, 5% CO2 for 5 hours. A background control cultured without any 
peptides was included in each sample. As a positive control, samples were cultured with 50 
ng/ml phorbol myristate acetate and 1 μg/ml ionomycin. After the 5 hour incubation, plates were 
stored at 4°C for overnight. Cells were first stained for surface marker specific antibodies (anti- 
CD3-PerCP-Cy5.5 and anti-CD8 PE), then fixed and permeabilized with saponin containing 
FACS solution and intracellular stained with cytokine-specific antibodies (anti-IFN-γ PE-Cy5, 
IL-2 APC, TNF-α APC-Cy7). Then these cells were washed, fixed, and analyzed by flow 
cytometry within 12 hours of staining. The proportions of fluorochrome-labeled cells were 
assessed with a BD Canto flow cytometer and analyzed by FlowJo software (provided by Dr. 
Mario Roederer, NIH). Data was typically collected from 50,000 lymphocytes. 
5.4.10 Flow Cytometry and analysis 
Stained cells were analyzed using a BD Canto flow cytometer. FCS files were analyzed using 
FlowJo software (version 7.2.2). Cells in the lymphocyte gate were gated on CD3+CD8+ or 
CD3+CD8- cells, and gates for individual cytokines and CD107a were established with control 
cells stained only for CD3 and CD8. Cells in the cytokine and CD107a gates were analyzed with 
boolean gating to generate the percentage of cells expressing each combination of functional 
markers. Background expression values were subtracted from peptide-stimulated values for each 
sample. Graphical representation of functionality was achieved using SPICE software kindly 
provided by Dr. Mario Roederer. For SPICE analysis, individual mice with no HIV-1-p55-
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specific response were excluded. A threshold value of the 75% confidence values of negative 
percentages for each T cell subset was used. 
5.4.11 Statistics 
Statistical analyses were performed using GraphPad Prism version 4. Except where noted, p 
values were determined using 1-tail two-sample Student’s t-test with unequal variance. Results 
were considered significant if p<0.05. 
5.5 RESULTS 
5.5.1 Screening of immunodominant HIV-1 Gag peptide pools for use in measuring  
HIV-1 specific cellular immune responses in immunized mice 
There is very little information available on the mouse immunodominant T cell epitopes within 
the HIV-1 Gag region. Therefore a study was initiated to identify immunodominant T cell 
epitopes within the HIV-1 Gag region in the mouse, the results of which were then used for 
subsequent screening of HIV-1 Gag immune responses in immunized mice. Since yields of cells 
from mucosal tissues of mice are generally limited, the use of a few immunodominant peptides 
instead of all the peptides spanning the Gag region is beneficial for increasing sensitivity of 
immune response assays. To identify the immunodominant epitopes, 5 different overlapping 
peptide pools of 15 mer encompassing the entire HIV-1 Gag region were created from the HIV-1 
Gag peptides (Figure 10B). The mice were immunized subcutaneously with purified HIV-1 Gag 
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protein along with complete Freund’s adjuvant and boosted 10 days later with the same antigen 
in the presence of incomplete Freund’s adjuvant (Figure 10A). The mice were sacrificed 14 days 
after the final boost and splenocytes were harvested and used as responder cells. An IFN-γ 
ELISPOT was performed by incubating these splenocytes with the HIV-1 Gag peptide pools for 
24 hours to stimulate antigen specific T cells. As shown in figure 10C, peptide pool 3 (p24 
region) and pool 5B (p7/p6 region) showed higher HIV-1 Gag specific IFN-γ responses when 
compared to other peptide pool regions, and therefore they were selected for future ELISPOT 
assays. Also, although pool 4 (p24 region) and pool 5A (p24 and p7 region) showed similar 
responses, pool 5A was selected for future use due to the inclusion of peptides from both p24 and 
p7 regions of Gag. Overall we selected the peptide pools 3 and 5B for use as antigen-specific 
stimulants in all subsequent studies described below. 
Pool 1 (2)
Pool 4  (2) & 
5A (19)
Pool 2 (12)
Pool 3 (7)
Pool 5B (19)
Boost with HIV-p55
Collected Spleen
HIV-p55 (s. c.)
ELISPOT
10 days
14 days
A B
C
 
Figure 10. Screening of HIV-1 Gag peptide pools. 
(A) A group of 10 mice each were immunized with HIV-1 Gag (p55) protein and (subcutaneously) with adjuvants and a group of 
5 control mice immunized with PBS as show. Spleen was harvested for use in ELISPOT assays. (B) HIV-1 Gag protein was 
divided into 5 different peptide pools as shown. (C) IFN-γ secreting splenocytes stimulated with the different HIV-1 Gag peptide 
pools as determined by ELISPOT. Error bars representing standard error of the mean. 
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5.5.2 Cellular immune responses induced by immunization with recombinant C. 
perfringens and VLPs 
Initially a pilot study was performed to evaluate and compare immune responses induced by 
heterologous versus homologous prime boost vaccination approaches using recombinant C. 
perfringens (CP) and VLPs. This initial study was performed with a total of three groups: (1) 
both prime and boost were done with VLP (VLP), (2) priming was done with VLP and boosting 
with CP (VLP/CP) and (3) adjuvant control group in which animals received CT adjuvants only 
without vaccine (control). Cells from spleen, Peyer’s patches (PPs) and mesenteric lymph nodes 
(MLN) were analyzed for HIV-1 Gag specific IFN-γ secreting cells by incubating with Gag- 
*
*
*
*
 
Figure 11. HIV-1 specific IFN-γ secretion by T cells from mice immunized with either VLP alone (VLP), VLP 
along with Cp-Gag (VLP/Cp) or adjuvants only (Control).  
Three groups of five mice each were intranasally immunized with either VLP in a prime boost approach (VLP) or with 
combination of Cp-gag (orally) in a prime boost approach. Immunized mice spleen, Peyer’s Patches and Mesenteric lymph nodes 
were harvested for use in ELISPOT assays. For statistical analysis p values were determined by Student’s t-test. * p value < 0.05, 
compared to control groups.  
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specific peptide pools in an ELISPOT assay. When compared to the adjuvant control group there 
was a significant increase in the HIV-1 Gag specific T cell response in spleen and PPs of both 
the VLP and VLP/CP groups, and in MLN of the VLP/CP group (Figure 11). However no 
significant differences were observed between VLP and VLP/CP groups in the responses from T 
cells isolated from spleen, MLNs and PPs of the immunized mice. However, PPs had the highest 
number of HIV-1 specific IFN-γ producing cells compared to spleen and MLN cells in all 
immunized mice. HIV-1 Gag specific humoral immune responses were also evaluated by 
measuring the IgG1 and IgA subtype of antibodies in sera and mucosal fluids (feces and 
intestinal washes) from the immunized mice. There were no significant HIV-1 specific humoral 
immune responses observed in the mucosal or systemic compartments of the immunized mice 
(data not shown). This study was performed using non optimized doses of cholera toxin (CT) and 
CpG oligodeoxynucleotides (ODN) as adjuvants. The failure to see a difference between the 
VLP and VLP/CP immunized groups might be a result of the use of suboptimal doses of 
adjuvants that was given orally with CP. Therefore a study was initiated to select proper 
adjuvants and their doses that could induce maximum mucosal immune responses. 
5.5.3 Optimization of oral adjuvants  
The cholera toxin (CT), mutant heat-labile toxin (LT [R192G], mLT), or unmethylated cytosine-
phosphate-guanine oligodeoxynucleotides (CpG ODN) were selected as adjuvants for use with 
recombinant C. perfringens. The optimization of dose and adjuvant capacity of these adjuvants 
was carried out by delivering them along with recombinant C. perfringens expressing SIV Gag 
(Cp-SGag) via the oral route to naïve mice. Small groups of mice (3 mice per group) were orally 
administered with 150 ug/mice SIV Gag (measured by western blot) in the form of bacterial 
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culture of Cp-SGag and varying doses of CT, mLT, or CpG ODN. Control groups consisted of 
mice vaccinated orally with Cp-SGag without any adjuvants. Cells from PPs were assayed for 
SIV Gag specific IFN-γ production using an ELISPOT assay. As shown in Figure 12 A, the 
groups that received 5 μg CT, 1 μg mLT, or 50 μg of CpG ODNs demonstrated higher number of 
SIV Gag specific IFN-γ secreting T cells when compared to the other groups. However within 
these three adjuvants groups, 1 ug of mLT and 50 ug of CpG-ODNs groups showed superior 
responses. Surprisingly delivery of Cp-SGag with higher doses of CT (10 or 50 ug ) or mLT (5, 
25 or 50 ug) gave lower cellular responses when compared to delivery with lower doses of CT 
(5ug) or mLT (1 ug), although this was not statistically significant. IgG1 and IgG2a levels in 
serum and IgA levels in fecal extract and intestinal wash were low in all groups, with no 
difference observed between vaccinated mice and the PBS control group (data not shown). 
Since both CpG ODN (50 ug) and mLT( 1 ug) induced greater cellular responses than CT 
(5ug) when used with Cp-SGag, combinations of different doses of CpG ODNs with mLT were 
further tested to determine their optimum combination to induce the strongest cellular immune 
responses. Groups of 4 mice were inoculated orally with Cp-SGag with various combinations of 
doses CpG ODNs with 1 μg mLT, and the cellular immune responses in the PPs were compared 
with groups of mice that received each adjuvant dose alone or Cp-SGag alone (Figure 12 B). 
IFN-γ ELISPOT assays of cells from PPs showed that 50 μg CpG ODN combined with 1 ug of 
mLT generated a higher but statistically insignificant cellular immune response than 25 or 100 
μg CpG ODN combined with mLT. The group of mice that were immunized with Cp-SGag 
along with 1 ug mLT and 50 ug of CpG-ODNs was the only group that displayed a significantly 
higher cellular response compared to the groups that received Cp-SGag without adjuvants. 
Therefore this combination of 1 ug mLT and 50 ug of CpG-ODNs were chosen as the adjuvant 
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dose to be used with recombinant C. perfringens in all subsequent oral immunizations. The 
probable reason for the higher responses seen in the mLT and CpG ODNs adjuvant combination 
groups compared to groups with either adjuvant alone could be that mLT and CpG ODNs 
stimulate immune cells through separate signaling mechanisms which are additive in nature.  
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Figure 12. HIV-1 specific IFN- γ secretion by T cells from mice immunized with recombinant C. perfringens 
expressing SIV Gag in combination with various doses of adjuvants.  
(A)  SIV Gag specific IFN-γ ELISPOT results from PPs, each bar representing average of 3 mice per group with error bars 
representing standard error of the mean. (B) Adjuvants CpG- ODN and mLT was combined in various doses and orally 
administered to mice along with antigen CP-Gag. This experiment is representative of 2 individual studies. Mean results from the 
PPs of 4 mice per group are shown with error bars representing standard error of the mean. 
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5.5.4 Comparison of cellular immune responses induced by homologous and heterologous 
immunization approaches  
The HIV-1-Gag specific T cell responses were evaluated after using homologous (recombinant 
C. perfringens or VLP alone) or heterologous (combining both recombinant C. perfringens and 
VLP) prime boost immunization approaches. The optimized combination doses of mLT and CpG 
ODN were used along with orally administered recombinant C. perfringens expressing HIV Gag 
(Cp-Gag) and intranasally delivered HIV-1 VLPs. Groups of 10 mice were immunized with 
different prime-boost regimens as described (Table 1), and the resulting systemic and mucosal 
immune responses were investigated.  
Table 1. First immunization schedule 
Immunization 
group Prime (week 0) 1
st Boost (week 3) 2nd Boost (week 6) 3rd  Boost (week 9) 
PBS Adjuvant only Adjuvant only Adjuvant only Adjuvant only 
CP/CP Cp-Gag Cp-Gag Cp-Gag Cp-Gag 
VLP/VLP VLP VLP VLP VLP 
CP/VLP Cp-Gag Cp-Gag VLP VLP 
VLP/CP VLP VLP Cp-Gag Cp-Gag 
 
Mice were primed with either Cp-Gag (150 ug/mice) or VLP (20 ug/mice) were boosted 
thrice at three week intervals with either vector in a homologous manner where the Cp-Gag 
primed group received Cp-Gag as boost (CP/CP) and the VLP primed group received VLP as 
boost (VLP/VLP) or in a heterologous manner where Cp-Gag or VLP primed groups were 
boosted with VLP (CP/VLP) or Cp-Gag (VLP/CP) respectively. The control group received 
adjuvants in PBS without any antigen at each inoculation. Fourteen days after the final booster 
immunization, mice were sacrificed. Peripheral blood serum, intestinal washes, and fecal 
samples were collected and examined for humoral immune responses. Cells isolated from spleen, 
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mesenteric lymph node (MLN), and Peyer’s patches (PPs) were examined for cellular immune 
responses. 
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Figure 13. HIV-1 specific IFN- γ secretion by T cells from Peyer’s patches (A) and spleen (B) of mice 
immunized with various prime-boost regimens.  
Average HIV Gag specific IFN-γ ELISPOT results from (A) Peyer’s Patches (PPs) and (B) Spleen.  Results are shown in bar 
graph, with each bar representing the average of 6 mice per group and are shown with error bars representing standard error of 
the mean. For statistical analysis p values were determined by Student’s t-test with unequal variance. *p<0.05,compared to the 
homologous and adjuvant alone groups. **p<0.05 compared to the VLP/CP, homologous and adjuvants alone groups.  
 
An IFN-γ ELISPOT assay was used to determine the number of IFN-γ secreting HIV-1 
Gag specific immune cells in the mucosal and systemic compartments of the immunized mice. 
As shown in Figure 13 in general all heterologous groups which received both Cp-Gag and VLP 
had significantly higher IFN-γ secreting cells in all tissue compartments compared to the 
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homologous groups. As observed in previous immunization studies, PPs had the higher numbers 
of HIV-1 specific IFN-γ producing cells compared to spleen. Furthermore, the CP/VLP group 
showed the highest level of T cell immune responses. The results from this study indicated that 
the mice primed with Cp-Gag followed by boosting with VLPs induced significantly higher 
levels ( p<0.05)  of HIV-1 specific cellular immune responses in spleen (Figure 13A), and PPs 
(Figure 13B), compared to either vaccine vector alone .  
Low levels of IgG1 antibody responses were detected in sera from mice that were 
immunized with Cp-Gag and VLP in a prime boost approach compared to mice that received 
either construct alone (Figure 14A). No IgA antibody responses could be detected in mucosal 
samples from feces and intestinal washes (Fig 14B and C). This suggests that the use of Cp-Gag 
and VLP together in a prime boost (heterologous) approach induces low level of antigen specific 
IgG1 antibody response in serum, but not in mucosal compartments. Therefore this vaccination 
approach needs further optimization to obtain higher levels of systemic and mucosal humoral 
responses.  
0
0.2
0.4
0.6
0.8
1
PBS CP/CP VLP/VLP CP/VLP VLP/CP
1:100
1:400
1:1600
1:6400
0
0.05
0.1
0.15
0.2
0.25
0.3
PBS CP/CP VLP/VLP CP/VLP VLP/CP
1:5
1:50
0
0.025
0.05
0.075
0.1
0.125
0.15
PBS CP/CP VLP/VLP CP/VLP VLP/CP
1:5
1:50
A B
C
 
Figure 14. OD405 values for anti-HIV-1 antibodies present in serum (IgG, A), fecal washes (IgA, B) and 
intestinal washes (IgA, C) of immunized mice. 
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5.5.5 Cellular immune responses measured in the GI tract lamina propria  
The lamina propria (LP) is the effector site of the GI tract immune system and is known to 
contain a large number of lymphocytes. Therefore induction of antigen specific lymphocytes in 
the LP is a desired property for mucosal vaccines that target the GI tract. Since LP tissues were 
not analyzed in the previous immunization study, a second similar immunization study was 
performed to assay if Cp-Gag and VLP prime-boost immunization can induce antigen specific 
cellular immune responses in the LP. Table 2 describes the immunization schedule, which differs 
from the previous schedule as shown in table 2, a single VLP immunization was used and the 
number of booster immunizations was reduced to two.  
Table 2. Second immunization schedule 
Immunization group Prime (week 0) 1st Boost (week 3) 2nd Boost (week 6) 
Control Adjuvant only Adjuvant only Adjuvant only 
VLP1 VLP PBS PBS 
VLP2 PBS PBS VLP 
CP/VLP Cp-Gag Cp-Gag VLP 
VLP/CP VLP Cp-Gag Cp-Gag 
CP Cp-Gag Cp-Gag PBS 
 
Systemic and mucosal tissue samples were used to harvest cells from spleen, PPs, MLN 
and LPs tissue compartments. Lymphocytes were isolated from the tissues and were assayed for 
HIV-1 Gag specific IFN-γ production in an ELISPOT (Figure 15). As shown in Figure 15D   
spleen of  mice that were primed first with Cp-Gag and then boosted with VLPs (Cp/VLP group) 
had the significantly higher number of IFN-γ secreting HIV-1 Gag specific immune cells 
compared to mice that were primed first with VLPs and then boosted with Cp-Gag (VLP/Cp 
group) (p <0.05).  The Cp/VLP group also had the highest number of IFN-γ secreting HIV-1-
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Gag specific immune cells compared to mice immunized with either Cp-Gag or VLPs alone 
(p<0.01). A similar trend was seen in cells from both the PPs and MLNs of immunized mice 
although the magnitude of the responses in MLN was comparatively lower (Figure 15B, C).  
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Figure 15. HIV-1 specific IFN- γ secretion by T cells from Lamina propria (A), Peyer’s patches (B), MLN (C) 
and spleen (D) of mice immunized with various prime-boost regimens. * p<0.05 when compared to all other 
groups.  
Average HIV Gag specific IFN-γ ELISPOT results from (A) Lamina Propria (LP), (B) Peyer’s Patches (PPs),(C) Mesenteric 
Lymph Node(MLN) and (D) Spleen (SP). Results are shown in bar graph, with each bar representing the average of 10 mice per 
group and are shown with error bars representing standard error of the mean. For statistical analysis p values were determined by 
student’s t-test. *p<0.05, compared to all other vaccinated groups. 
 
The LP is an effector site of the gut that has been shown to be important in HIV-1 
infections [38]. In the LP of the immunized mice, both the Cp/VLP and the VLP/Cp group 
induced almost similar numbers of IFN-γ secreting HIV-1 Gag specific immune cells that were 
significantly higher than that seen in all other tissue compartments (p< 0.01). In addition, these 
CP/VLP and VLP/CP groups significantly increased number of HIV-1 Gag specific IFN- γ from 
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mice immunized with either Cp-Gag or VLPs alone (Figure 15A). It was also observed that the 
LP tissue compartment had the highest number (4000- 5000 IFN-γ secreting cell/106 cells) of 
IFN-γ secreting HIV-1-Gag specific immune cells as compared to T cell responses in all other 
tissue compartments (200-400 IFN-γ secreting cell/106 cells). However no antibody responses 
were detected in mucosal and systemic samples from all immunized mice (data not shown).  
These data indicate that the priming with Cp-Gag stimulates mucosal cellular immune 
responses in the gut that are improved by intranasal boosting with HIV-1 VLPs and this 
heterologous prime-boost approach was most effective in the strong induction of antigen specific 
responses in the LP, an important effector site of the gut. 
5.5.6 Measurement of functionality of HIV-1 Gag specific T cells in mucosal and systemic 
compartments 
The ability of T cells to produce multiple cytokines on a single cell basis in response to antigenic 
stimuli has been shown to be associated with a protective response against infection. Therefore 
to further explore the potential of Cp-Gag and VLPs as a mucosal priming vaccine, the 
multifunctional quality of cellular responses were measured, after immunization in both the PP, 
inductive site and LP, the effector tissue. The quality of HIV-1 Gag specific immune responses 
in these sites were assessed by performing an intra-cellular cytokine staining of cells stimulated 
with HIV-1 Gag peptides followed by multiparametric flow cytometry analysis  
Table 3. Third immunization schedule 
Immunization group Prime (week 0) 1st Boost (week 3) 2nd Boost (week 6) 
PBS/ADJ Adjuvant only Adjuvant only Adjuvant only 
CP-VLP Cp-Gag Cp-Gag VLP 
VLP-CP VLP Cp-Gag Cp-Gag 
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As shown in table 3, in this study there were 3 groups of ten mice, each were inoculated 
with oral Cp-Gag or nasal VLP and. boosted at 3 weeks interval with either Cp-Gag or VLP. 
Mice in control group received only adjuvants in PBS. All mice were sacrificed 14 days after the 
last booster immunization. Cells were harvested from spleen, PPs and LP tissues of the 
immunized mice and the presence of antigen specific T cells were evaluated in these cell 
preparations by both ELISPOT and intracellular staining using multiparametric flow cytometry 
techniques.  
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Figure 16. HIV-1 specific IFN- γ secretion by T cells from Lamina propria (A), Peyer’s patches (B) and spleen 
(C) of immunized mice. 
Average HIV Gag specific IFN-γ ELISPOT results from (A) Lamina Propria (LP). (B) Peyer’s Patches (PPs).and (C) Spleen 
(SP). Results are shown in bar graph, with each bar representing the average of 10 mice per group and are shown with error bars 
representing standard error of the mean. For statistical analysis p values were determined by student’s t-test using 2 tailed, 
unequal variance parameters. *p<0.05, compared to control group, where mice received adjuvants only. 
 
The results from the ELISPOT reinforce the findings from previous immunization studies 
that the HIV-1 specific mucosal immune responses in both the effector (LP) and inductive sites 
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(PP) of the GI tract were significantly higher in mice immunized using recombinant Cp-Gag and 
VLPs in heterologous prime-boost approaches compared to mice immunized with either Cp-Gag 
or VLPs alone (Figure 16). LP, the effector site of the gut, had the highest number of HIV-1 
specific IFN-γ producing cells as compared to spleen and Peyer’s patches cells in all immunized 
mice as measured by ELISPOT. These results further provide evidence to the ability of Cp-Gag 
and VLP prime boost approaches in inducing strong mucosal immune response in the GI tract, 
one of the major sites of early HIV-1 replication. 
To evaluate other functions of the HIV-1 Gag-specific GI tract mucosal cells, cells were 
stained for the cytotoxic degranulation marker CD107a, and intracellular cytokine staining was 
performed to detect IFN-γ, TNF-α, and IL-2 production in these cells. These four immune 
functions were then detected by multiparameter flow cytometry. Cells were surface stained for 
CD3 and CD8 to differentiate CD8+ and CD8- T cells.  
5.5.7  Individual cytokine secreting cells in PP and LP 
The percentage of cells producing each cytokine in the PP and LP was calculated from flow 
cytometry results (Figure 17). In both mucosal compartments - PP and LP, the percentage of 
IFN-γ producing CD8+ cells were highest. Surprisingly the percentage of IL-2 producing cells 
from all three groups was lowest when compared to other cytokines. In the cytokine response 
seen in PPs; the CP/VLP group displayed highest IFN-γ and TNF-α production compared to the 
VLP/CP group (Figure 17A). On the other hand, the VLP/CP group displayed slightly higher 
percentage of cells expressing IL-2 compared to the CP/VLP or control groups. There was very 
low expression of the surface marker CD107a. However, the percentage of cells expressing 
CD107a was slightly higher in the VLP/CP group compared to the other groups. Overall in PPs, 
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the CP/VLP group displayed slightly higher percentage of cells expressing all cytokines 
compared to the VLP/CP group.  
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Figure 17. Percentage of CD8+ T cells secreting the indicated cytokines in response to stimulation with HIV-1 
Gag peptides in the PPs (A) and LP (B).  
HIV Gag-specific IL-2, TNF-α, and IFN-γ  and CD107a production from CD8+ CD3+ cells was detected via intracellular 
staining and samples were analyzed using flow cytometry and percent of cells with any cytokine response was determined. Bars 
represent the average values from 10 mice per group plus standard error of the mean. 
 
The LP had the higher percentage of antigen specific CD8+ T cell responses to HIV-1 
Gag compared to PP (Figure 17B). In contrast to the results from PPs, the LP had higher 
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percentages of HIV-1 Gag specific cells expressing CD107a on their surface, especially in the 
VLP/CP group compared to the CP/VLP or control groups (p<0.05). IFN-γ production by HIV-1 
Gag specific cells in the LP was almost comparable in both the CP/VLP and VLP/CP groups. 
TNF-α production by HIV-1 Gag specific cells in the LP was also similar in all three groups, 
even in control group that did not receive any immunogen. It was also observed that in the LP, 
there was a comparatively higher amount of non-specific cytokine secreting cells in the control 
group than in the PP. Overall these results demonstrate that mucosal immunization with Cp-Gag 
and VLPs lead to the induction of HIV-1 Gag specific T cell populations that can secrete 
multiple cytokines in the mucosal tissue compartments of the GI tract. 
5.5.8 Measurement of multifunctionality of antigen specific T cells 
The multifunctional characteristic (2 or more functions) of the HIV-1 Gag specific T cells from 
PP and LP were further evaluated. All mice displayed production of at least one of the assayed 
cytokines in response to HIV-1 Gag in T cells from the PP. There were higher percentages of 
cells producing two or more cytokines in mice from the CP/VLP and VLP/CP groups compared 
to those in the control group. The mice from the CP/VLP group had slightly higher numbers of 
HIV-1 Gag specific multifunctional CD8+ T cells that secrete all three cytokines - IL-2, TNF-α, 
and IFN-γ and CD107a compared with the VLP/CP or control groups (Figure 18). Overall, the 
level of multifunctionality (secreting all three cytokines and CD107a) of PP CD8+ T cells was 
greater in mice from the CP/VLP group compared to all other groups. Surprisingly mice from the 
control group also displayed lower levels of multifunctionality compared to the other groups. 
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Figure 18. Multifunctional T cell responses in the Peyer’s patch an inductive site of the GI tract, of 
immunized mice. 
Data generated from Boolean-gated CD8+ cells from Peyer’s patches stained for CD107a, IL-2, TNF-α and IFN-γ were analyzed 
for concurrent functionality using SPICE software. A, The average percentage of total response for each combination of functions 
is shown with error bars representing standard error of the mean. B, The average percentage of total response at each level of 
multifunctionality is represented by slices in pie charts. 
 
As observed in the PP, mice in all groups had HIV-1 Gag specific T cells in the LP that 
produced at least one cytokine (Figure 19). However, in contrast to the PP response, in LP the 
VLP/CP group was the only group that displayed multifunctionality (secreting all three cytokines 
and CD107a) of LP CD8+ T cells compared to all other groups. HIV-1 Gag specific cells having 
all four function were not detected in CP/VLP group as was seen in PPs. Surprisingly control and 
CP/VLP groups displayed almost comparable level of cells having either 1, 2 or 3 cytokine 
functions. These results indicate that the T cells in the LP appear to have higher levels of 
background cytokine production since the control group also had high amounts of non specific 
cytokine production. The LP is an effector site of the GI tract and therefore is under constant 
 86 
antigenic exposure in the GI tract which might lead to an overall inflammatory environment 
producing cytokines and other inflammatory molecules. 
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Figure 19. Multifunctional T cell responses in the Lamina propria, an effector site of the GI tract, of 
immunized mice. 
Data generated from Boolean-gated CD8+ cells from lamina propria stained for CD107a, IL-2, TNF-α and IFN-γ were analyzed 
for concurrent functionality using SPICE software. A, The average percentage of total response for each combination of functions 
is shown with error bars representing standard error of the mean. B, The average percentage of total response at each level of 
multifunctionality is represented by slices in pie charts. 
 
5.5.9 Characterization of cellular immune responses 
Adaptive immunity is mediated mainly by T cells comprised of CD4+ and CD8+ T cells. CD4+ T 
cells are also known as T-helper cells and have an important role in the initiation and 
maintenance of immune responses against pathogens. On the other hand, CD8+ T cells are 
known as cytotoxic T cells that can directly mediate killing of cells infected with pathogens. 
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Therefore a study was performed to determine whether immune responses induced by Cp-Gag 
and VLP prime-boost immunization approaches was mediated by CD4+ or CD8+ T cells. 
Magnetic beads coupled to either CD4 or CD8 antibodies were used to deplete cells expressing 
them from the cell preparations of spleen, PPs and LP tissues obtained from immunized mice 
(Figure 20). Then the presence of antigen specific immune responses in these CD4+ or CD8+ 
depleted cells were assayed by an ELISPOT as described before. 
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Figure 20. Representative flow cytometry analysis of cells from spleen of immunized mice after negative 
selection for CD4+ or CD8+ cells using magnetic beads.  
(A) Total spleen cell population before depletion, (B) CD8+ cell depleted spleen population, and (C) Percentages of CD4+ and 
CD8+ cells after depletion in the adjuvant alone group (left), CP/VLP group (middle) and VLP/CP group (right). 
 
In the spleen, similar numbers of IFN-γ secreting HIV-1 Gag specific immune cells in the 
total cell population was observed as before, with the CP/VLP group having the highest number 
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of IFN-γ secreting cell (Figure 21A). The numbers of IFN-γ secreting HIV-1 Gag specific 
immune cells were higher in the CD8+ cell depleted populations compared to those depleted of 
CD4+ cells. Surprisingly, depletion of either CD4+ or CD8+ cells led to increased numbers of 
IFN-γ secreting HIV-1Gag specific immune cells in comparison to the non depleted total cell 
population in the VLP/CP group only, whereas in the rest of the groups the non depleted total 
cell population had the highest numbers compared to the CD4+ or CD8+ depleted populations. 
Therefore these results indicate that there was more contribution of the CD4+ cells to the antigen 
specific responses seen in the spleen compared to the CD8+ cells. 
In the PPs, we found similar results for the CD4+ or CD8+ cell depleted populations as 
seen in the spleen (Figure 21 B). The CP/VLP group had the highest numbers of IFN-γ secreting  
HIV-1-Gag specific immune cells in either the total or CD4+/CD8+ cell depleted populations 
amongst all immunization groups. In the CP/VLP group, the CD4+T cells generally contributed 
more to the antigen specific responses compared to the CD8+ T cells. On the other hand, in the 
rest of the groups both CD4+ and CD8+ depleted cells showed similar levels of IFN-γ secreting 
HIV-1-Gag specific immune cells. Therefore we found that the CP/VLP had the highest antigen 
specific responses amongst all immunization groups and the CD4+ cells were the major 
contributors to this cellular response. 
Similarly, the antigen specific cellular responses in the LP were highest in the CP/VLP 
group, although both CD4+ and CD8+ cells had similar levels of antigen specific responses 
(Figure 21 C). Also as seen earlier the magnitude of responses was highest in the LP of 
immunized mice when compared to other tissue compartments and that the Cp/VLP group was 
best in inducing strong antigen specific responses in this important mucosal tissue compartment. 
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Figure 21. HIV-1 specific IFN- γ secretion by T cell subsets separated using negative selection by magnetic 
beads from spleen (A), Peyer’s patches (B), and Lamina propria (C) of mice immunized with various prime-
boost regimens.  
5.6 DISCUSSION 
Since HIV-1 is largely transmitted via mucosal surfaces and immune cells in the GI tract are 
primary viral targets during early infection that remains a reservoir during the period of chronic 
infection [18, 37, 38, 157], induction of mucosal immunity is important for effective prevention 
of HIV-1 infection and propagation. Stopping infection at the mucosa may ablate infection or 
lower the severity of resulting infection; however, once the virus has established the infection, it 
cannot be eliminated from the host [157]. Therefore a vaccine which can prevent virus 
transmission at mucosal surfaces by inducing strong mucosal HIV-1 specific CD8+ and CD4+ T 
cells at the port of entry would be an effective HIV-1 vaccine candidate. 
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C. perfringens has been developed as a vaccine vector against HIV-1 and SIV. It has 
been shown previously that these recombinant bacteria can deliver intact target protein to the GI 
tract immune cells. VLPs also present an attractive mucosal vaccine vector and have been shown 
to induce potent mucosal immune responses. Therefore in this study, a combination of Cp-Gag 
and VLPs was used in a heterologous prime boost immunization strategy. Mucosal vaccination 
typically requires the use of adjuvant to overcome tolerance and induce an appropriate immune 
response. Therefore the appropriate mucosal adjuvants and their optimal dose for use with Cp-
Gag and VLPs were first determined.  
Adjuvants have been shown be important for induction of immune responses after 
mucosal immunizations specially those using the oral route [149]. This is due to the phenomenon 
of oral tolerance or unresponsiveness of the GI tract immune system against dietary and 
commensal bacteria, which is important to maintain tissue integrity by preventing harmful 
inflammatory responses in the intestine. Therefore the use of adjuvants is necessary to induce 
strong GI tract immune responses as it provides additional signals that induce an inflammatory 
environment which is required for generation of mucosal immune responses. The two adjuvants 
used in this study – mLT and CpG ODNs, have been widely used in oral vaccines. The E. coli 
mutated heat labile enterotoxin - mLT or LT (R192G) is a mutant form of LT which has been 
shown to retain immunogenicity and adjuvanticity with greatly reduced toxicity in animal 
models, and clinical trials [164, 207, 208]. CpG ODNs are synthetic oligodeoxynucleotides 
(ODN) that contain unmethylated CpG motifs which mimic the immunostimulatory activity of 
bacterial DNA [209]. In this study, an additive effect on the immune response was observed 
when the combination of mLT and CpG ODNs were used as adjuvants and this might be due to 
the fact that they bind to distinct receptors and induce separate signaling mechanisms.  
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In the current study, immunization with Cp-Gag exclusively stimulated GI tract mucosal 
cellular immunity, but induced low level of systemic cellular immunity. However, oral priming 
using Cp-Gag followed by an intranasal VLP boost enhanced mucosal immunity and improved 
systemic cellular immune responses. These results suggest that even when immunity induced by 
an oral vaccine is at undetectable levels, immunity exists that can be boosted with an unrelated 
vector. The striking part of this study was the induction of the strongest cellular immune 
responses against HIV proteins within the LP compartment of the gastrointestinal tract amongst 
all other GI tissue compartments in the immunized mice. 
Higher percentages of vaccine-induced antigen-specific cells that express both IFN-γ and 
TNF-α have been observed in gut-associated tissue of monkeys who resisted infection as 
compared to those vaccinated animals who became infected [203]. The CD8+ T cells and the 
CD4+ T cells that secrete 3+ cytokines, i.e. TNF-α, IL-2 and IFN-γ, have been associated with 
control of HIV infection. [101, 203]. Therefore, in this study multifunctional mucosal immune 
responses were also evaluated in the GI tract after the heterologous prime-boost immunizations. 
This study investigated whether the priming with an oral Cp-Gag vaccine followed by boosting 
with intranasal VLP inoculation could improve mucosal responses in the GI tract. The results 
presented in this report showed that mice that were first primed with Cp-Gag and then boosted 
with VLP induced stronger systemic and mucosal cellular responses to HIV Gag as compared to 
control groups in which mice were immunized with either Cp-Gag or VLP alone. In addition, 
multifunctional CD8+ T cells secreting all four cytokines seemed to be higher in mice primed 
with Cp-Gag and boosted with VLP than mice that were vaccinated with only one vector. These 
results were inherently problematic due to relatively high background levels of staining. In 
addition, the absence of a live/dead cell marker in the flow staining limits the reliability of the 
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information obtained from positive intracellular cytokine staining of cells since dead cells are 
known to give false positive signals due to their inherent auto fluorescence and ability to non 
specifically bind to antibody conjugates. Therefore, although these results show a trend towards 
inducing multifunctional T cells by prime-boost heterologous immunization, because of the 
limitation of the multiparametric flow staining assays they have to be accepted with these 
caveats.  
On the other hand, the characterization of the contribution of CD4+ and CD8+ T cells to 
the HIV-1 Gag cellular responses observed in the immunized mice provided greater insight into 
the exact nature of the immune responses elicited by the heterologous prime boost approach 
using Cp-Gag and VLPs. The presence of both CD8+ and CD4+ T cell responses against 
lentiviruses in the systemic and mucosal compartments has been associated with protection from 
HIV-1 and SIV infections [98, 105, 210]. The presence of abundant virus specific CD4+ T cells 
in the GI tract that act as helper cells for virus specific cytotoxic CD8+ T cells can help eliminate 
the virus infected cells in the GI tract early on during infection. It has been shown that adaptive 
CD4+ T cells are critical for the generation of effective anti viral CD8+ T cell responses and that 
long-term protection from disease will be afforded only by T cell vaccines for HIV-1 that 
provide a balanced induction of CD4+ and CD8+ T cell responses and protect against early 
depletion of CD4+ T cells post infection [211]. It has also been shown that the presence of both 
HIV-1 specific CD4+ and CD8+ T cells at the site of mucosal infection is sufficient to control 
viral replication in the SIV-macaque model [212, 213]. Therefore mucosal HIV-1 vaccines that 
elicit strong and robust anti viral CD4+ and CD8+ T cells at mucosal sites like the genital and GI 
tracts that are early targets of HIV-1 infection will provide the best opportunity for protection 
against mucosal HIV-1 infections.  
 93 
In this study, it was observed that the antigen specific cellular immune responses that 
were generated by the heterologous prime boost approach using Cp-Gag and VLPs were 
mediated by not just CD8+ T cells alone, but by both CD4+ and CD8+ T cells. Both T cell subsets 
contributed generally equally to the overall HIV Gag responses and moreover these responses 
were highest in the mucosal compartments of the GI tract. Therefore the immunization strategy 
described here that leads to the development of potent mucosal cellular immune responses might 
lead to protection against HIV-1 infection at mucosal sites. 
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6.0  OVERALL SUMMARY OF THE RESULTS 
Clostridium perfringens (Cp) has been considered as a vehicle for antigen delivery to the GALT. 
Recombinant clostridia carrying HIV-1 Gag genes were constructed to express large amount of 
these HIV-1 Gag protein. After preparation of the vaccine constructs we performed in vitro and 
in vivo experiments to evaluate antigen specific cellular and systemic immune responses to 
recombinant clostridia expressed HIV-1 Gag protein (Cp-Gag). Bone marrow derived dendritic 
cells were observed to mature and stimulate HIV-1 Gag specific T cell responses following 
exposure to Cp-Gag. Since mucosa is an important portal for HIV-1 entry and infection to the 
human body, in vivo experiments to evaluate mucosal immune response induced by Cp-Gag and 
HIV-1 VLPs were performed. Since strong cellular immune responses at mucosal compartments 
are important in control of HIV-1 infection, my dissertation study was focused on eliciting anti 
HIV-1 mucosal immune response in order to control HIV-1 infection. 
First, immune responses in mice after oral administration of Cp-Gag alone were 
evaluated. Antigen specific IFN-γ ELISPOT revealed very low or almost undetected level of 
humoral and mucosal T cell immune responses was detected. The vaccination approach was then 
improved by combining HIV-1 VLPs with Cp-Gag vaccine in a prime boost approach. Slightly 
higher antigen specific immune responses were detected in the orally administered Cp-Gag 
followed by intranasal inoculation of VLPs in a prime boost strategy. The T cell immune 
response was further enhanced in systemic and mucosal compartments, such as spleen, PP, LP, 
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and mesenteric lymph nodes by the co-administration of optimized mucosal adjuvants mLT and 
CpG-ODN along with Cp-Gag and VLP. However, the prime-boost strategy generated strongest 
cellular immunity in the effector LP tissue in GI tract. Both CD4+ and CD8+ T cell subsets 
contributed to the overall HIV-1 specific cellular immune responses in spleen and GI tissues, 
such as PP and LP. Altogether, this dissertation work demonstrates that priming with orally 
delivered Cp-Gag followed by intranasal inoculation of VLP stimulates highest cellular immune 
response in the mucosal compartments of the GI tract such as PP and LP when compared to the 
systemic compartment such as spleen. Therefore the immunization strategy with heterologous 
vectors using oral priming with recombinant C. perfringens expressing HIV-1 Gag followed by 
intranasal VLP boosting leads to the development of potent mucosal cellular immune responses.  
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7.0  FINAL DISCUSSION 
HIV-1 transmission occurs mainly through sexual exposure of mucosal surfaces of the genital 
tract and rectum to virus and virus-infected cells. Recent studies have shown that mucosal gut 
associated lymphoid tissue (GALT) is the major target of HIV-1 infection and replication [18, 
37, 38, 47, 157]. These findings imply that the induction of strong virus-specific immunity at 
mucosal sites may be crucial for an effective anti-HIV-1 vaccine. An ideal vaccine must generate 
both humoral and cellular responses in order to control HIV-1 infection. However, the challenge 
remains to induce neutralizing antibodies, now major efforts have been made to develop vaccines 
that can maximize cell-mediated mucosal immunity, especially in the intestine and genital tract. 
Studies on rhesus monkeys have demonstrated that the presence of both anti viral CD4+ and 
CD8+ T cells at the site of mucosal infection is sufficient to control  SIV replication at 
mucosa.[[212, 213]. Therefore a vaccine which induces strong HIV-1 specific CD8+ and CD4+ T 
cells at mucosal sites like the genital and GI tract should be able to prevent HIV-1 infection and 
transmission at mucosal surfaces.  
One of the challenges of HIV vaccine design is the complexity of inducing immune 
responses in the GI tract. It is often difficult to deliver sufficient amounts of vaccine antigen to 
the relevant GALT inductive tissues, namely PPs or LP. Due to the importance of GI tract 
mucosal immunity against HIV-1 and SIV [38], a strategy to improve the mucosal immunity at 
GI tract is desirable. Both oral and rectal inoculation strategies are under investigation for the 
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purpose of delivering HIV/SIV vaccine antigen to immune inductive tissues of the GI tract [115]. 
Studies have shown that oral immunization strategies have induced immune responses in the GI 
tract, whereas nasal immunization strategies have been reported to induce robust immune 
responses in the respiratory and genitourinary tracts [136-138]. 
Several studies using invasive bacteria such as Lactococcus lactis, Salmonella enterica 
serovar Typhimurium and Listeria monocytogenes as oral vaccine delivery vectors have been 
performed [214-220]. Shigella flexneri has also been used for intranasal inoculation [221-223]. 
These studies generated mostly systemic cellular immune response in the spleen, even after oral 
or nasal deliver. Therefore, in this study a bacterial based vector which can induce strong cellular 
immune responses in mucosal compartments was explored. A non-cytotoxic, non invasive C. 
perfringens based mucosal vaccine against HIV-1 and SIV was developed. The unique 
characteristics of C. perfringens make it an attractive mucosal vaccine model against HIV-1 and 
SIV. First advantage is the presence of its inducible and strong cytopathic enterotoxin (cpe) 
promoter. The harsh conditions of the GI tract induce the cpe promoter and lead to production of 
large amounts of cpe protein. The strength of the cpe promoter is demonstrated by the fact that 
cpe enterotoxin production in the human intestine accounts for up to 15% of total bacterial 
protein, which accumulates in cytoplasmic inclusion bodies inside the mother cell. Therefore, 
placing an antigen of interest, like HIV-1 Gag under the cpe promoter will enable it to produce 
large amount of protein in the GI tract. Since the HIV-1 Gag antigen is present in inclusion 
bodies of recombinant C. perfringens expressing HIV-1 Gag (Cp-Gag), the HIV-1 Gag protein is 
protected from stomach acid and degrading enzymes of the small intestine, while the bacterial 
vector travels through the upper GI tract. This would deliver high amounts of intact viral antigen 
to inductive immune tissues in the gut. The goal of this study was to deliver HIV-1 Gag antigen 
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via C. perfringens to GI tract mucosal tissues and induce strong immune response against the 
antigen. To achieve this goal a recombinant C. perfringens based vaccine vector was constructed 
that produced high level of HIV-1 Gag protein under sporulating conditions.  
The production of an immune response that is reactive against a variety of viral proteins 
is thought to aid in protection from disease progression. As the virus mutates its proteins in an 
attempt to evade immunity, a broad immune response increases the likelihood of the immune 
system to successfully recognize viral protein epitopes and control virus. The incorporation of 
various viral proteins into a vaccine would thus be beneficial. Many different viral proteins could 
be placed under the control of the cpe promoter in the C. perfringens vector. The incorporation 
of an envelope protein for expression by C. perfringens was considered, since the envelope has 
been shown to carry antigenic determinants that elicit strong cellular and humoral immune 
responses in acutely and chronically HIV-1 infected humans, and in HIV-1 vaccinated humans. 
However, it is realized that envelope protein synthesized from cpe promoter will not be 
glycosylated, as the bacterium lacks the capacity to correctly glycosylate this protein in a manner 
useful for successful antibody response formation against most portions of gp120. However, 
certain portions of the envelope gp41 molecule do not require glycosylation-controlled structural 
constraints for production of neutralizing antibodies and are also quite conserved among all HIV-
1 types, thus making gp41 an attractive HIV-1 protein to incorporate into recombinant C. 
perfringens. However, repeated attempts to obtain HIV-1 envelop gene expressing recombinant 
clostridia were not successful. The reason for lack of envelope protein expression from clostridia 
was not very well understood. It’s possible that sequences present in HIV-1 envelope may be 
toxic for bacteria or have bactericidal effect. Several laboratories have observed that the 
glycoprotein components of HIV-1 and other retroviruses have variety of toxic effects on 
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bacterial cultures [224, 225]. It has been also shown that amino terminal portion of HIV-1 
envelope transmembrane (TM) domain contains a highly conserved sequence [226] that is 
structurally similar to an amino terminal sequence present on the fusion protein of myxoviruses, 
which has been shown to have high cytopathic effect. Molecular modeling studies of protein 
sequences identified two positively charged, highly amphipathic amino acid segments in the 
cytoplasmic tail of the transmembrane (TM) envelope protein of HIV-1 which has a very high 
antibacterial effect [227]. Therefore HIV-1 envelope TM domains may play an important role in 
cytopathicity. In other studies it has been shown that some virally derived peptides have 
antimicrobial properties [228]. These virally derived peptides are designated as lentivirus lytic 
peptides (LLPs). Like cationic peptides, LLP1 is a highly effective against many antibiotic-
resistant microbial pathogens. Moreover, LLP1 readily kills S. marcescens, an important 
organism of ophthalmologic concern which is generally resistant to cationic peptides. Therefore 
the lack of expression of HIV-1 envelope by recombinant C. perfringens could be due to the 
cytotoxic properties of viral peptides and TM domains of viral envelope proteins like gp140. 
The bacteria-based vaccines are thought to interact with DCs and, in the case of L. 
monocytogenes, can stimulate cytotoxicity against antigen-specific target cells in vitro [229]. The 
results of the current study demonstrate that in vitro exposure of GI tract mucosal BMDCs to the 
Cp-Gag vaccine leads to effective stimulation of HIV Gag specific cells, indicating that this 
interaction may support immune response induction in the GI tract. 
Another challenge in the development of orally delivered vaccines is oral tolerance. 
While oral tolerance is an important phenomenon to protect unnecessary inflammatory 
responses, it presents an obstacle in the development of oral vaccines. There are some successful 
oral vaccines, but most of them are live attenuated forms of the pathogenic strains. These live 
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attenuated vaccines administered by the oral route are associated with effective development of 
systemic and mucosal immune responses, superior protection against pathogen infection, and 
ease of administration. The use of attenuated strains of pathogens can overcome the tolerogenic 
response in the GI tract since they mimic natural infection without causing pathogenesis and thus 
lead to protective immune responses. Although this is an attractive approach, a major drawback 
of such an approach is the possibility of reversion of the attenuated strain to the wild type 
pathogenic strain. Therefore alternative ways to avoid oral tolerance and induce strong mucosal 
immune response need to be explored. Mucosal vaccination typically requires the use of adjuvant 
to overcome tolerance and drive the induction of an appropriate immune response. The co 
administration of mucosal adjuvants with recombinant bacterial vaccine vectors is expected to 
alter the type of immunity induced by oral vaccination. Therefore in the current study strong 
mucosal adjuvants were selected and their optimal doses were used along with the mucosal 
vaccine constructs. The combination of 1 μg mLT and 50 ug of each CpG ODNs resulted in the 
highest percentage of IFN-γ producing T cells when compared with the other adjuvant 
combinations.  
Heterologous prime-boost vaccination has been shown to be an efficient way of inducing 
T cell responses in animals and in humans. [230]. It was shown that sequential immunization 
with two different replicating recombinant viral vectors could induce a strong CD8+ T cell 
response [231]. Further studies in mice have shown that the heterologous prime-boost strategy 
that combines two different vectors encoding the same antigen is more efficient in inducing cell-
mediated immune responses than the use of a single vector and is surprisingly immunogenic with 
non replicating vectors [123, 124]. Studies in nonhuman primates have revealed that the prime-
boost approach induces strong cellular response and can lead to protection against diseases such 
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as malaria or simian-HIV in primates [61, 125, 232, 233]. In this study heterologous 
immunization of Cp-Gag and VLP through oral and nasal route has been explored. This 
heterologous immunization in a prime-boost mode induced immune response in both mucosal 
and systemic tissue compartments. The HIV Gag specific IFN-γ immune responses were highest 
in the mucosal compartments, PP and LP, compared to the responses seen in the spleen or 
mesenteric lymph nodes (MLN). It is not very clear why responses at these systemic sites were 
comparatively low. It is possible that the time points used for analysis may not represent time 
points when draining LNs contain antigen-specific IFN-γ producing cells. The lower immune 
responses observed in MLN could be due to the difference in trafficking of PP and LP antigen 
presenting cells, specifically dendritic cells. LP dendritic cells travel to the MLN to present 
antigen, whereas dendritic cells from PP primarily relocate from the subepithelial dome (SED) to 
T and B cell areas of the PP and do not frequently migrate to MLN [234-236]. Therefore, even if 
the PP dendritic cells were exposed to Cp-Gag and they efficiently acquire Gag antigen, the 
responses they stimulate will not be detectable in the MLN. Higher responses in the MLN and 
systemic tissues have been observed following oral vaccination with other bacterial-based 
vectors, and this may be due to the fact that these other vectors deliver protein to cells in the LP 
through direct infection and subsequent active replication [215, 220, 237, 238]. For example, a 
Salmonella-based vaccine delivers vaccine antigen by entering macrophages in the LP [215, 
237]. 
The combination of IFN-γ with other functions of CD8+ T cells appears to associate with 
effective CD8+ CTL responses and control of SIV/HIV infection [98, 239]. Therefore, in the 
current study, multifunctional mucosal cellular immune responses in the GI tract after 
immunization with the mucosal vaccine constructs were evaluated. Despite low systemic 
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humoral and cellular responses with this vaccine strategy, strong cellular responses in the 
inductive (PPs) and effector (LP) sites of the GI tract were observed. Additionally, this study 
investigated whether the mucosal immune responses that were primed with oral Cp-Gag vaccine 
could be boosted with a subsequent intranasal VLP inoculation. The results obtained indicate that 
mice that were first primed with Cp-Gag and then boosted with VLP induced stronger systemic 
and mucosal cellular responses to HIV-1 Gag compared with the groups in which mice were 
immunized with either Cp-Gag or VLP alone.  
In this study, immunization with Cp-Gag and VLP alone could induce very low levels of 
HIV-1 Gag specific IgA and IgG antibodies in the mucosal and serum samples of immunized 
mice, respectively. However, IgG1 antibody levels in serum of mice primed with Cp-Gag and 
boosted with VLP were higher than those from mice in control groups, although these were not 
significant. It is possible to induce a humoral response creating antibodies through the use of 
adjuvants that promote Th2-type immune responses. The adjuvants utilized in the majority of the 
current study, CpG ODNs and mLT, are known to promote Th1-type immunity rather than Th2-
type responses. The use of cholera toxin (CT) has been recognized as promoting Th2-type 
immunity, particularly when the CT or CTB subunit is conjugated directly to the antigen being 
delivered. Thus, it seems possible that the inclusion of Th2-promoting adjuvants may aid in the 
formation of antibody responses as a result of oral vaccination with a C. perfringens-based 
vaccine.  
A number of studies using viral vectors such as adenovirus, vaccinia virus, papilloma 
virus, and adeno-associated virus have been reported in which cellular immune responses were 
observed in mucosal compartments [240, 241]. However, these studies were mostly focused on 
measuring cellular responses in PP, which is the inductive site of the GI tract. There were only 
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few studies where HIV-1 specific cellular immune responses were measured in the LP, which is 
an effector site of the GI tract and is important in early HIV infection. In one such study, an 
intrarectally delivered modified vaccinia Ankara based vaccine provided high level of antigen-
specific IFN-γ secreting cells (800-900 sfc/106 cells) in the LP [242]. In the current study, oral 
immunization of Cp-Gag followed by an intranasal boost with VLP produced even stronger 
antigen-specific IFN-γ secreting cells (3000-4000 sfc/106 cells) in the LP. Presence of this strong 
HIV specific immune response in LP could be very important in controlling viral replication 
during early HIV-1 infection in the gut. 
The results of the current study demonstrate that in vivo oral inoculation with 
recombinant C. perfringens primes GI tract cellular immune responses. These findings suggest 
that recombinant C. perfringens based vectors should be considered as a mucosal HIV-1 vaccine 
vector. Oral administration of vaccines is often preferable to and more cost effective than 
inoculation strategies requiring sterile needles, so including recombinant C. perfringens in a 
vaccination regimen involving boosting with VLPs would have the added benefit of non needle 
inoculations. Given the importance of the GI tract in HIV-1 infection, it is vital to pursue 
development of vaccine vectors such as recombinant C. perfringens that may induce effective 
anti-viral immunity in the gut.  
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7.1 PUBLIC HEALTH SIGNIFICANCE  
Currently there are no vaccines available against HIV-1, while HIV-1 infection has become a 
global scourge. Therefore the development of a low cost effective HIV-1 vaccine is of immediate 
need. In this proposal, I have investigated the use of non-invasive bacterial-based protein 
delivery system directed at the GI tract using recombinant C. perfringens. I have explored 
different mucosal immunization approaches using recombinant C. perfringens expressing HIV-1 
proteins and HIV-1 VLPs to generate robust mucosal immune responses against HIV-1. The 
proposed vaccine constructs hold great promise for developing a practical vaccine against HIV-1 
due to its safety, low production cost and easy administration. 
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8.0  FUTURE DIRECTIONS 
The current study provides a novel strategy to develop a heterologous vaccine against HIV-1 
using recombinant C. perfringens expressing HIV-1 Gag protein (Cp-Gag) and HIV-1 virus like 
particles (VLPs) in order to induce strong HIV-1 Gag specific cellular immune responses in 
mucosal tissues. However through the course of these studies many pertinent questions have 
arisen that could not be addressed due to constraints of time. In this section I will briefly mention 
some of the key areas that could be further studied.  
Despite the induction of strong cellular immune responses at mucosal tissue 
compartments such as Peyer’s patches (PP) and Lamina propria (LP), weak cellular responses 
were detected in spleen or mesenteric lymph nodes (MLN). It is possible that the time points 
used to analyze the HIV-1 Gag specific cellular immune responses in PP and LP may not be 
optimal for spleen and MLN. Therefore a study could be performed to assay cellular immune 
responses in the spleen and MLN at different time points after immunization. 
Although strong cellular immune responses were generated at mucosal sites, there were 
very minimal or no humoral responses at systemic and mucosal tissues compartments. Therefore, 
a study should be performed to elicit humoral immune responses using the current heterologous 
approach. One of the approaches could be the use of adjuvants which are known to induce Th2 
type immune responses that are known to be important for induction of humoral immune 
responses. The adjuvants used in this study - CpG ODNs and mLT are known to promote Th1 
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type rather than Th2 type responses. The use of CT has been recognized as promoting Th2-type 
immunity, therefore it can be included as another adjuvant to enhance humoral responses 
induced by the current heterologous vaccine approach. 
Although the multiparameter flow cytometry analysis showed trends towards the 
generation of polyfunctional CD8 T cells in animals immunized with Cp-Gag and VLPs, it needs 
to be re-examined with better gating strategy to evaluate induction of polyfunctional CD8 T cells 
in response to vaccination with Cp-Gag and VLPs.  
Recently the SIV-p27 gene was inserted into the chromosome of C. perfringens where 
the viral gene is expressed under the control of cpe gene promoter and thereby negating the use 
of antibiotic resistant plasmids carrying the gene of interest under the cpe promoter. The safety 
of this vector has been further rendered by inactivating two more toxin gens, alpha and theta. 
Therefore this C. perfringens vector would be safer than the Cp-Gag used in the current study.  
The incorporation of various viral proteins into a vaccine could be beneficial since the 
production of a broader immune response against a variety of viral proteins is thought to aid in 
protection from disease progression. Therefore other HIV-1 genes like env, pol, and nef could be 
placed under control of the cpe promoter in recombinant C. perfringens and these recombinant 
clostridia could be tested for induction of HIV-1 specific immune responses against these 
proteins. It is possible that the mixture of recombinant C. perfringens expressing multiple HIV-1 
proteins would be able to induce broad and strong mucosal and systemic immune responses 
against HIV-1, which might be important for protection against HIV-1 infection. 
A challenge experiment will help in assessing whether mucosal T cell immune responses 
against HIV-1 Gag in the GI tract are protective against a mucosal HIV-1 infection. This can be 
done in initially in mice with intra-vaginal challenge with recombinant vaccinia virus expressing 
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HIV-1 Gag (rVV-Gag). Studies are going on in our laboratory to establish vaccinia challenge 
model in mice and measure efficacy of protection conferred by vaccination with Cp-Gag and 
VLPs in a prime boost mode. If the Cp-Gag and VLPs in a prime boost mode is found to be 
protective in mice, this could be extended to monkey model. Similar immunization studies could 
be performed using recombinant C. perfringens expressing various SIV genes in the SIV-
macaque model to induce strong mucosal and systemic immune responses against SIV and to 
determine the ability of these responses to protect against a mucosal challenge with a pathogenic 
SIV, which is the closest animal model of HIV/AIDS. Furthermore, if it is demonstrated that 
these vectors can induce protective immune responses in the SIV-macaque model, then clinical 
trials can be planned to assess the safety and immunogenecity of recombinant C. perfringens 
based vectors in humans. 
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